SEARCH
検索詳細
伊師 雪友 (イシ ユキトモ)
| 北海道大学病院 脳・神経・感覚器科 | 助教 |
| 教育イノベーション機構 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野■ 担当教育組織
研究活動情報
■ 論文- YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth.
Kentaro Mineji; Katerina Petrosky; Ryosuke Otsuji; Yasuhide Makino; Yuji Kibe; Eita Uchida; Daichi Hagita; Neha Singaravelan; Yukitomo Ishi; Shigeru Yamaguchi; Long-Sheng Chang; Samantha Gadd; Rintaro Hashizume
bioRxiv : the preprint server for biology, 2026年08月07日, [国際誌]
英語, 研究論文(学術雑誌), UNLABELLED: Neurofibromin 2 (NF2) deficiency is a driver of meningioma and other cancers, yet transcriptional effectors that sustain NF2-deficient tumors remain poorly defined. We identify carboxypeptidase A4 (CPA4) as an effector of YAP-TEAD signaling in NF2-deficient meningioma. Transcriptomic profiling identified CPA4 as a consistently upregulated effector. Across patient cohorts and specimens, CPA4 expression was enriched in NF2 -mutant and chromosome 22q-deleted meningiomas and associated with higher tumor grade and chromosome 1p loss. CPA4 depletion impaired proliferation, disrupted cell-cycle, DNA-replication, and DNA-repair programs, suppressed intracranial tumor growth, and prolonged survival. Integrated epigenomic and functional assays identified CPA4 as a direct YAP-TEAD transcriptional target. CPA4-high meningioma models exhibited preferential sensitivity to YAP-TEAD inhibition, while verteporfin and the clinical-stage TEAD inhibitor VT3989 reduced CPA4 expression, suppressed orthotopic tumor growth, and prolonged survival. These findings uncover a targetable YAP-TEAD-CPA4 dependency in NF2-deficient meningioma and identify CPA4 as a potential biomarker for TEAD- directed therapy. STATEMENT OF SIGNIFICANCE: CPA4 links NF2 loss to oncogenic YAP-TEAD transcription, sustains meningioma growth, and marks tumor sensitivity to pharmacologic TEAD inhibition. These findings establish CPA4 as a tumor-promoting effector and potential biomarker of an actionable pathway shared across NF2- deficient cancers. - Therapeutic Courses of Presumed Intracranial Immature Teratoma Diagnosed Based on Increased Alpha-Fetoprotein.
Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Sogo Oki; Ryosuke Sawaya; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Kentaro Nishioka; Takayuki Hashimoto; Hiromi Okada; Emi Takakuwa; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
Journal of child neurology, 8830738261446144, 8830738261446144, 2026年05月07日, [国際誌]
英語, 研究論文(学術雑誌), Intracranial immature teratoma (ImT) is one of the non-germinomatous germ cell tumors, and elevated serum alpha-fetoprotein (AFP) value is a crucial clinical diagnostic indicator of ImT. In this retrospective study conducted among patients diagnosed with intracranial ImT, diagnostic procedures, therapeutic courses, histopathologic diagnosis, and prognosis were reviewed. Among 106 patients with intracranial germ cell tumors, 11 were diagnosed with ImT and treated since 2000. ImT was diagnosed via biopsy or based on mild or moderate serum AFP elevation of 10-500 ng/mL. Complete remission via chemoradiotherapy was achieved in only 2 patients (18%); 5 patients (45%) suffered from growing disease during treatment; and 7 patients required salvage tumor resection. The 10-year progression-free and overall survival rates were 76.2% and 87.5%, respectively. The therapeutic courses of ImT varied. Notably, cases in which treatment was applied considering ImT were highly prone to experience growing disease during treatment. - Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study.
Naoya Kaneko; Shuntaro Morikawa; Megumi Endo; Nozomi Hishimura; Liu Zhitong; Takeshi Yamaguchi; Hisato Segoe; Jutaro Abe; Kazumi Oura; Saori Sawai; Minako Sugiyama; Yukayo Terashita; Shinsuke Hirabayashi; Yuko Cho; Akie Nakamura; Yukitomo Ishi; Seishin Takao; Yuto Matsuo; Shigeru Yamaguchi; Takayuki Hashimoto; Atsushi Manabe
Endocrine journal, 73, 6, 729, 740, 2026年04月10日, [国内誌]
英語, 研究論文(学術雑誌), Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4-12.5) years, the median post-radiation follow-up was 19.5 (9.7-34.7) years, and the median CSI dose was 25.2 (23.4-36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3-11.7) years, 6.9 (5.4-8.1) years, and 23.4 (23.4-36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols. - Role of antiseizure medication in postoperative late seizure and survival among patients with newly diagnosed glioblastoma: A multicenter retrospective study.
Akihiro Inoue; Makoto Ohno; Yawara Nakamura; Yoshitaka Narita; Daisuke Kawauchi; Yoshiteru Shimoda; Mitsuto Hanihara; Tomoo Matsutani; Shigeo Ohba; Natsumi Yamashita; Narushi Sugii; Kuniaki Saito; Ichiyo Shibahara; Shunsaku Takayanagi; Joji Ishida; Masamichi Takahashi; Noriyuki Kijima; Yuta Mitobe; Nayuta Higa; Masato Saito; Ryosuke Matsuda; Yukitomo Ishi; Kohei Nakajima; Shinji Yamashita; Kaoru Tamura; Iori Ozono; Taiki Setoguchi; Tetsuya Negoto; Kosuke Katayama; Atsushi Kambe; Daisuke Kuga; Kazuhiro Tanaka; Takeshi Okuda; Koichiro Sumi; Takahiro Kanda; Shigeki Takada; Kojiro Wada; Yu Fujii; Yu Kawanishi; Hideyuki Arita; Yuichi Sato; Takuya Yonemochi; Ryohei Otani; Shinichiro Koizumi; Yoshiki Arakawa; Takeharu Kunieda
Neuro-oncology advances, 8, 1, vdag205, 2026年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: We conducted a multicenter study to investigate the utility of postoperative antiseizure medication (ASM) in the occurrence of late seizure in glioblastoma. In addition, we analyzed whether postoperative ASM affects survival. METHODS: 1132 consecutive patients with newly diagnosed glioblastoma at 39 centers were enrolled. In patients treated with postoperative ASM (levetiracetam [LEV], lacosamide [LCM], or perampanel [PER]), as well as in those who received no medication, the cumulative incidence of late seizure, adverse events, and survival outcomes were analyzed. RESULTS: In total, 1099 patients (female: 482, male: 617, mean age: 67.2 years) were included, among whom, 287 developed postoperative late seizure. The mean onset time of late seizure was 193.6 days after surgery. Postoperative ASMs were administered in 628 cases, LEV in 344, LCM in 124, and PER in 160. The cumulative incidence of late seizure at 12 months was as follows: no medication in 30.9%, LEV in 17.8%, LCM in 28.8%, and PER in 16.2%. Multivariable analysis disclosed that LEV and PER displayed significantly lower cumulative incidences of postoperative late seizure compared with no medication and LCM. By contrast, median progression-free survival/overall survival did not significantly differ among ASMs. However, during the 12-24 month interval, the PER group demonstrated a more favorable prognosis than the other groups. CONCLUSIONS: LEV and PER after glioblastoma surgery were associated with a reduced risk of late seizure compared with LCM or no medication. LEV or PER may be considered as postoperative ASMs to optimize seizure control and potentially help preserve patients' QOL. - Unexpected [18F] Fluciclovine Uptake in Pilocytic Astrocytoma: A Pediatric Case Report.
Hiroto Koga; Shiro Watanabe; Kenji Hirata; Yukitomo Ishi; Shigeru Yamaguchi; Kohsuke Kudo
Clinical nuclear medicine, 51, 7, e499-e501, 2025年11月20日, [国際誌]
英語, 研究論文(学術雑誌), A 5-year-old asymptomatic boy underwent MRI, which revealed a mass lesion in the septum pellucidum suspected to be a glioma. [18F]Fluciclovine PET, which provides insight into amino acid metabolism, revealed high uptake (SUVmax, 2.37; TBR, 3.56), which was consistent with high-grade glioma. In contrast, [18F] Fluorodeoxyglucose PET showed low uptake (SUV max: 2.2; TBR: 0.29). Partial resection and histopathology confirmed pilocytic astrocytoma, a WHO grade 1 tumor, with KIAA1549-BRAF fusion. High [18F] Fluciclovine uptake in pilocytic astrocytoma may reflect amino acid transporter expression, which may lead to overestimation of the WHO grade. Awareness of this pitfall is essential in pediatric neuro-oncology. - Primary spinal cord malignant B-cell lymphoma successfully treated with tirabrutinib at relapse: a case report.
Yukitomo Ishi; Hiroaki Motegi; Soichiro Takamiya; Ai Shimizu; Takashi Mori; Sogo Oki; Motoyuki Iwasaki; Shigeru Yamaguchi; Miki Fujimura
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 35, 6, 3631, 3636, 2025年11月17日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Primary spinal cord lymphoma rarely occurs, and the treatment strategy has not been standardized. Tirabrutinib (TIR) shows therapeutic efficacy for cases with primary central nervous system lymphoma (PCNSL) with B-cell pathology arising intracranially, but the evidence for primary spinal cord cases has not been reported. We present a case of primary spinal cord lymphoma successfully treated with TIR at relapse. METHODS: Case report. RESULTS: A 58-year-old male presented with progressive numbness from the neck down and neck pain. Magnetic resonance imaging revealed an intramedullary lesion in the cervical spine from the cervico–medullary junction to the C7. Biopsy was performed, and the pathological diagnosis was diffuse large B-cell lymphoma. Four cycles of chemotherapy with rituximab, methotrexate, procarbazine, and vincristine (R-MPV) were ineffective, but remission of the cervical lesion was achieved after subsequent irradiation. However, after 1 month, a de novo lesion was observed in the lower thoracic spinal cord. Tumor remission was achieved with TIR, and the patient showed no relapse for 42 months after starting TIR. CONCLUSION: TIR administration should be considered for relapsed primary spinal cord lymphomas similar to those with intracranial occurrence. - Fluciclovine-PET Uptake in Microcystic Meningioma Mimicking High-grade Glioma: A Case Report.
Junki Takenaka; Kenji Hirata; Shiro Watanabe; Yukitomo Ishi; Kohsuke Kudo
Clinical nuclear medicine, 50, 10, 975, 977, 2025年10月01日, [国際誌]
英語, 研究論文(学術雑誌), A 69-year-old asymptomatic woman underwent magnetic resonance imaging (MRI), revealing a left parietal lobe tumor suspected to be a high-grade glioma (HGG). [ 18 F]Fluciclovine-positron emission tomography (PET), which reflects amino acid metabolism, showed moderate uptake [SUVmax 1.4, tumor-to-normal ratio (TNR) 1.9], consistent with HGG, whereas [ 18 F]fluorodeoxyglucose-PET findings demonstrated low uptake (SUVmax 2.5, TNR 0.22), which is atypical for HGG. Surgical and pathologic investigations confirmed the diagnosis of microcystic meningioma, a rare subtype classified as grade 1. Microcystic meningiomas mimic HGG on magnetic resonance imaging and [ 18 F]fluciclovine-PET due to l -amino acid transporter expression, complicating diagnosis. - Assessment of prognostic value and development of predictive model for prolonged lymphopenia in patients with glioblastoma following chemoradiotherapy.
Shuhei Takahashi; Kentaro Nishioka; Takashi Mori; Shigeru Yamaguchi; Yukitomo Ishi; Keiji Kobashi; Yoichi M Ito; Zen-Ichi Tanei; Hiromi Kanno-Okada; Shinya Tanaka; Hidefumi Aoyama
Journal of radiation research, 66, 5, 542, 550, 2025年08月11日, [国際誌]
英語, 研究論文(学術雑誌), Lymphopenia during chemoradiotherapy (CRT) for glioblastoma has been shown to be a poor prognostic factor. However, the relationship between prolonged lymphopenia (PL) after CRT and prognosis remains unclear. This study aimed to explore the relationship between PL and glioblastoma prognosis and develop a predictive model for PL risk. We analyzed 87 patients with primary glioblastoma who underwent postoperative CRT with 60 Gy in 30 fractions of radiotherapy and temozolomide. PL was defined as grade 2 or higher lymphopenia 1 month after the completion of CRT. We conducted survival analysis, identified risk factors for PL, and developed a predictive model for PL risk. Of the 87 patients, 41 developed PL, and progression-free survival (PFS) was significantly shorter in the PL group (median 8.0 months vs 15.4 months, P = 0.003). However, there was no significant difference in overall survival between the two groups. PL was also a significant factor for shorter PFS in multivariable analysis (P = 0.040). Brain V20Gy (percentage of brain volume receiving ≥20 Gy), gross total resection (GTR), and preoperative Karnofsky performance status (KPS) were identified as significant risk factors for PL. The predictive model showed that the risk of PL could be predicted by brain V20Gy, sex, age, GTR and preoperative KPS. PL was identified as a PFS shortening factor. Our model suggests that reducing irradiated brain volume may help prevent PL and could potentially improve glioblastoma prognosis by preserving cancer immunity. - Recurrence patterns and clinical outcomes in adult cerebellar glioblastoma.
Sogo Oki; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Masayuki Gekka; Zen-Ichi Tanei; Hiromi Kanno-Okada; Emi Takakuwa; Satoshi Tanaka; Takashi Mori; Kentaro Nishioka; Hidefumi Aoyama; Shinya Tanaka; Miki Fujimura
Acta neurochirurgica, 167, 1, 217, 217, 2025年08月08日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Cerebellar glioblastoma in adults is a rare brain tumor with poor outcomes. This study aimed to assess the clinical characteristics, genetic features, and prognosis of a series of cerebellar glioblastomas, with special attention to their recurrence patterns. METHODS: We retrospectively analyzed patients who underwent treatment between 2008 and 2023. The patient characteristics, treatment methods, genetic features, and prognoses were assessed. RESULTS: Among 274 cases of histological glioblastomas, eleven patients with cerebellar glioblastomas were identified. Pathological results revealed microvascular proliferation and/or necrosis in all cases. All patients underwent surgery and local radiotherapy combined with temozolomide chemotherapy. The median progression-free survival and overall survival were 15.3 months and 22.8 months, respectively. Subventricular zone involvement was recognized in ten patients. Of the eight patients who experienced recurrence, seven had distant or disseminated recurrence, and only one experienced local recurrence. None of the tumors harbored mutations in the IDH1/2, H3F3A, or TERT promoters. Three patients showed negative expression of O6-methylguanine DNA methyltransferase (MGMT), and four patients showed positive expression. CONCLUSIONS: In our cohort, cerebellar glioblastomas showed clinical characteristics such as recurrence patterns and genetic features such as IDH, H3F3A, and TERT promoter regions that differed from those of typical supratentorial gliomas. Further studies are necessary to fully elucidate the clinical characteristics. - 初発から10年以上経過して再手術が行われた毛様細胞性星細胞腫の病理学的検討
伊師 雪友; 山口 秀; 宮石 陸; 岡田 宏美; 小田 義崇; 杉野 弘和; 田中 伸哉; 大木 聡悟; 小柳 泉; 藤村 幹
Brain Tumor Pathology, 42, Suppl., 101, 101, 日本脳腫瘍病理学会, 2025年05月
日本語 - IDH変異型神経膠腫におけるCTでの石灰化所見と病理型の関連性
大木 聡悟; 山口 秀; 岡本 迪成; 伊師 雪友; 種井 善一; 岡田 宏美; 高桑 恵美; 田中 伸哉; 藤村 幹
Brain Tumor Pathology, 42, Suppl., 089, 089, 日本脳腫瘍病理学会, 2025年05月
日本語 - Wnt/β-カテニン経路は成長ホルモン産生下垂体腫瘍の細胞増殖を促進する
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
日本臨床分子医学会学術総会プログラム・抄録集, 60回, 47, 47, 日本臨床分子医学会, 2025年04月
日本語 - Ectopic expression of testis-specific transcription factor in driving cancer
Shimaa Hassan AbdelAziz Soliman; Zibo Zhao; Marta Iwanaszko; Benjamin Howard; Rintaro Hashizume; Ali Shilatifard; Lu Wang; Bin Zheng; Yukitomo Ishi; Sarah Gold; Ruxuan Qiu; Madhurima Das
Science Advances, 11, 11, eads4200, 2025年03月14日, [国際誌]
英語, 研究論文(学術雑誌), The testis-specific BET protein BRDT structurally resembles the ubiquitous BRD4 and is misexpressed in cancer, and we show that BRDT misexpression may affect lung cancer progression. BRDT knockdown in lung cancer cells slowed tumor growth and prolonged survival in a xenograft model. Comparative characterization of PTEFb complex participation and chromatin binding indicates BRD4-redundant and BRD4-distinct BRDT functions. Unlike dual depletion, individual BRD4 or BRDT knockdown did not impair transcriptional responses to hypoxia in BRDT-expressing cells, consistent with redundant function. However, BRD4 depletion/BRDT complementation revealed that BRDT can also release paused RNA polymerase II independently of its bromodomains as we previously demonstrated not to be required for Pol II pause/release function of BRD4, underscoring the functional importance of the C-terminal domains in both BRD4 and BRDT and their potential as therapeutic targets in solid tumors. Based on this study, future investigations should explore BRD4-distinct BRDT functions and BRDT misexpression driving cancer pathogenesis. - 髄液PLAPが検出感度以下であった成熟奇形腫とジャーミノーマの混合性胚細胞腫瘍の1例
大木聡悟; 山口秀; 岡本迪成; 伊師雪友; 寺下友佳代; 岡田宏美; 高桑恵美; 藤村幹
日本脳腫瘍学会学術集会プログラム・抄録集, 9, 8, 2025年02月24日, [国際誌]
英語, BACKGROUND: Diagnosing intracranial mixed germ cell tumors (GCTs) can be challenging due to intratumoral heterogeneity. Placental alkaline phosphatase (PLAP) in the cerebrospinal fluid (CSF) is a highly sensitive and specific marker for identifying pure germinomas and germinoma components within mixed GCTs. OBSERVATIONS: The authors present the case of a 6-year-old boy presenting with a 5-day history of vomiting and headache. Magnetic resonance imaging revealed a heterogeneously enhanced mass with cystic areas in the pineal region. Preoperative serum levels of alpha-fetoprotein and human chorionic gonadotropin, as well as CSF PLAP levels, were not elevated, leading to a preliminary diagnosis of mature teratoma. The tumor was completely resected, and pathological examination of the resected tissue confirmed a mature teratoma with germinoma components. Given the diagnosis of mixed GCT with a germinoma component, the patient underwent postoperative radiation chemotherapy. There has been no recurrence after 8 years of follow-up. LESSONS: In this case, the preoperative CSF PLAP level failed to predict the presence of a germinoma component. This report highlights a potential limitation of CSF PLAP as a diagnostic marker, noting that CSF PLAP may be undetectable if the germinoma is confined to a localized area. https://thejns.org/doi/10.3171/CASE24588. - Post-operative vestibular function outcomes evaluated by video Head Impulse Test in patients with non-vestibular schwannoma cerebellopontine angle tumors.
Keishi Fujiwara; Shinya Morita; Hiroaki Motegi; Shigeru Yamaguchi; Yukitomo Ishi; Kimiko Hoshino; Atsushi Fukuda; Hideaki Takeda; Yuji Nakamaru; Miki Fujimura; Akihiro Homma
Auris, nasus, larynx, 52, 1, 50, 58, 2025年02月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: To evaluate post-operative semicircular canal function in patients with non-vestibular schwannoma (VS) cerebellopontine angle (CPA) tumors by video Head Impulse Test (vHIT). METHODS: Fourteen patients with non-VS CPA tumors who underwent surgery. The gain in vestibulo-ocular reflex (VOR) was examined pre- and post-operatively for the semicircular canals in patients with non-VS CPA tumors. RESULTS: Ten of 14 patients showed semicircular canal dysfunction in one or more of the semicircular canals pre-operatively and VOR gain was significantly correlated with hearing function. Two patients showed improvement in one or more semicircular canals at 1 month after surgery compared to the pre-operative results. Significant improvements in VOR gain were observed when comparing VOR gain at 1 month and 6 months after surgery. CONCLUSIONS: Detailed evaluation of semicircular canal function was achieved by using vHIT in patients with non-VS CPA tumors. The good prognosis for vestibular function as evaluated by vHIT post-operatively was confirmed in patients with non-VS CPA tumors when compared to those in patients with VS. As improvement may occur post-operatively, surgical approaches that preserve the vestibular nerves and semicircular canals should be chosen for patients with non-VS CPA tumors, regardless of preoperative vestibular function. Even if vestibular function deteriorates immediately after surgery, it may improve over time if the nerve is preserved. - Long-term outcome and social-intellectual ability of patients with basal ganglia germinoma
Michinari Okamoto; Shigeru Yamaguchi; Ryosuke Sawaya; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Minako Sugiyama; Yuko Cho; Kentaro Nishioka; Takashi Mori; Takayuki Hashimoto; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
Pediatric Neurology, 165, 16, 21, Elsevier BV, 2025年01月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: In this study, we aimed at delineating the still ambiguous clinical characteristics and long-term outcomes of basal ganglia (BG) germinoma from the aspect of recurrence-free survival as well as social and intellectual activity. METHODS: We retrospectively reviewed medical records and imaging data for 12 patients with BG germinoma diagnosed and treated between 1996 and 2020, collecting the most recent status via medical records or telephone from the patients. RESULTS: The tumors involved the right and left sides and bilateral locations in three, seven, and two cases, respectively. The median follow-up period was 179 months. Six patients exhibited onset neuropsychologic symptoms, for example, cognitive decline or behavior disorder. We evaluated the intelligence quotient (IQ) in 10 patients and observed significantly lower IQ scores in six patients with neuropsychologic symptoms. Patients with right-sided lesions displayed average IQ levels (median 106), whereas those with left-sided or bilateral lesions had reduced IQ (median 67). A complete response was achieved by primary chemoradiotherapy in all patients. Three patients who underwent focal or whole-ventricle irradiation experienced recurrence, whereas no recurrence was observed in patients who received whole-brain irradiation (WBI). Concerning the neurocognitive outcomes, three and six patients with unilateral right and left lesions were living self-independently (Karnofsky Performance Status [KPS] ≧ 70), whereas the three remaining patients (one with left and two with bilateral lesions) had a dependent status (KPS <70). CONCLUSIONS: WBI is crucial for disease control in BG germinoma. Furthermore, lesion laterality might affect neuropsychologic symptoms including IQ at diagnosis and neurocognitive outcomes in BG germinoma. - CLINICAL FINDINGS AND PROGNOSIS OF ADULT GLIOBLASTOMA HARBORING ABRAF V600E MUTATION
Shigeru Yamaguchi; Yukitomo Ishi; Sogo Oki; Hiroaki Motegi; Kentaro Nishioka; Takashi Mori; Hiromi Okada; Zen-ichi Tanei; Shinya Tanaka; Miki Fujimura
NEURO-ONCOLOGY, 26, 2024年11月11日
英語 - Moyamoya syndrome after proton beam therapy in a pediatric patient with a pineal germ cell tumor and a germline polymorphism in RNF213.
Ting-Chun Lin; Haruto Uchino; Masaki Ito; Shigeru Yamaguchi; Yukitomo Ishi; Miki Fujimura
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 40, 11, 3873, 3878, 2024年08月21日, [国際誌]
英語, 研究論文(学術雑誌), The effects of RNF213, which leads to moyamoya disease susceptibility, on radiation-induced moyamoya syndrome (MMS) remain unknown. We report a case of MMS after proton beam therapy (PBT) was deployed to treat a brain tumor in a patient with an RNF213 polymorphism. An 8-year-old boy underwent whole ventricular and local PBT for a pineal germ cell tumor and was diagnosed with radiation-induced MMS 9 months later. He underwent right and left revascularization surgeries for cerebral hemodynamic compromise at 17- and 18-years of age, respectively. Genetic analysis revealed a heterozygous germline polymorphism RNF213 p.R4810K. This is the first report to suggest an association between RNF213 polymorphism and radiation-induced MMS. - Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.
Sogo Oki; Yukitomo Ishi; Ryosuke Sawaya; Michinari Okamoto; Hiroaki Motegi; Zen-Ichi Tanei; Masumi Tsuda; Takashi Mori; Kentaro Nishioka; Hiromi Kanno-Okada; Hidefumi Aoyama; Shinya Tanaka; Shigeru Yamaguchi; Miki Fujimura
Acta neurochirurgica, 166, 1, 263, 263, 2024年06月12日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: With the recent advent of genetic testing, IDH-mutant glioma has been found among adult brainstem gliomas. However, the clinical outcome and prognosis of IDH-mutant brainstem gliomas in adults have not been elucidated. This study aimed to investigate the clinical outcome, radiological findings, and genetic features of adult patients with IDH-mutant diffuse brainstem gliomas. METHODS: Data from adult patients with brainstem glioma at Hokkaido University Hospital between 2006 and 2022 were retrospectively analyzed. Patient characteristics, treatment methods, genetic features, and prognosis were evaluated. RESULTS: Of 12 patients with brainstem glioma with proven histopathology, 4 were identified with IDH mutation. All patients underwent local radiotherapy with 54 Gray in 27 fractions combined with chemotherapy with temozolomide. Three patients had IDH1 R132H mutation and one had IDH2 R172G mutation. The median progression-free survival and overall survival were 68.4 months and 85.2 months, respectively, longer than that for IDH-wildtype gliomas (5.6 months and 12.0 months, respectively). At the time of initial onset, contrast-enhanced lesions were observed in two of the four cases in magnetic resonance imaging. CONCLUSION: As some adult brainstem gliomas have IDH mutations, and a clearly different prognosis from those with IDH-wildtype, biopsies are proactively considered to confirm the genotype. - Pre- and post-operative semicircular canal function evaluated by video head impulse test in patients with vestibular schwannoma.
Keishi Fujiwara; Shinya Morita; Hiroaki Motegi; Shigeru Yamaguchi; Yukitomo Ishi; Kimiko Hoshino; Atsushi Fukuda; Makoto Kobayashi; Yuji Nakamaru; Miki Fujimura; Akihiro Homma
Auris, nasus, larynx, 51, 3, 542, 547, 2024年06月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: To evaluate pre- and post-operative semicircular canal function in patients with vestibular schwannoma (VS) by the video Head Impulse Test (vHIT). METHODS: Nineteen patients with VS who underwent surgery were enrolled in this study. The gain in vestibulo-ocular reflex (VOR) and the degree of scatter in catch-up saccades were examined pre- and post-operatively for the semicircular canals in VS patients. RESULTS: Ten of 19 cases (52.6 %) with VS were defined as demonstrating both superior vestibular nerve (SVN) and inferior vestibular nerve (IVN) impairment from the results of pre-operative vHIT. Hearing level and subjective vestibular symptoms showed significant correlations with pre-operative semicircular canal function. Compared to pre-operative vHIT results, VOR gains within 1 month after surgery were significantly reduced in all three canals; however, significant differences had disappeared in the anterior and posterior semicircular canals at 6 months after surgery. Cases of unknown origin had a significantly greater reduction in posterior semicircular canal function after surgery compared with those with disease of IVN origin. CONCLUSIONS: As vHIT could evaluate pre-operative vestibular nerve impairment, post-operative VOR gain reduction and the degree of vestibular compensation, semicircular canal function evaluated by vHIT provides a good deal of useful information regarding VS patients undergoing surgery compared to caloric testing, and vHIT should be performed pre- and post-operatively for patients with VS. - BET阻害療法はH3K27M変異を有するDiffuse Midline Gliomaへの放射線感受性を高める
渡邉潤; 渡邉潤; 渡邉潤; CLUTTER Matt; 佐々木貴浩; GULLETTE Michael; AMREEUNA Suri; 阿部幸喜; 伊師雪友; 高田望; SAMANTHA Gadd; 棗田学; ZHANG Zhiguo; BECKER Oren; 橋詰倫太郎; 橋詰倫太郎; 大石誠
日本脳腫瘍学会学術集会プログラム・抄録集, 134, 13, 2024年05月21日, [国際誌]
英語, Diffuse midline glioma (DMG) H3K27-altered is one of the devastating childhood cancers. Radiation therapy remains the only effective treatment yet provides a 5-year survival rate of only 1%. Several clinical trials have attempted to enhance radiation anti-tumor activity using radiosensitizing agents, although none have been successful. Given this, there is a critical need for identifying effective therapeutics to enhance radiation sensitivity for the treatment of DMG. Using high-throughput radiosensitivity screening, we identified bromo- and extra-terminal domain (BET) protein inhibitors as potent radiosensitizers in DMG cells. Genetic and pharmacologic inhibition of BET bromodomain activity reduced DMG cell proliferation and enhanced radiation-induced DNA damage by inhibiting DNA repair pathways. RNA-seq and CUT & RUN showed that BET bromodomain inhibitors regulate the expression of DNA repair genes mediated by H3K27 acetylation at enhancers. BET bromodomain inhibitors enhanced DMG radiation-response in patient-derived xenografts as well as genetically engineered mouse models. Together, our results highlight BET bromodomain inhibitors as radiosensitizer and provide a rationale for developing combination therapy with radiation for the treatment of DMG. - Increased CD44 expression in primary meningioma: its clinical significance and association with peritumoral brain edema.
Ryosuke Sawaya; Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Sumire Echizenya; Hiroaki Motegi; Noriyuki Fujima; Miki Fujimura
Journal of neurosurgery, 141, 1, 1, 8, 2024年02月09日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: CD44 is a major cell surface receptor involved in cell adhesion and migration. The overexpression of CD44 is a poor prognostic factor in many neoplasms, including meningiomas. The aim of this study was to investigate the association between CD44 gene expression and clinical signatures of primary meningiomas. METHODS: CD44 gene expression was quantitatively evaluated by snap freezing tumor tissues obtained from 106 patients with primary meningioma. The relationships between CD44 expression and clinical signatures of meningiomas, including histological malignancy, tumor volume, and peritumoral brain edema (PTBE), were analyzed. PTBE was assessed using the Steinhoff classification (SC) system (from SC 0 to SC III). RESULTS: CD44 gene expression in WHO grade 2 and 3 meningiomas was significantly higher than that in grade 1 meningiomas. In addition, CD44 expression increased with the severity of PTBE. Particularly, among the grade 1 meningiomas or small-sized tumors (maximum tumor diameter < 43 mm), CD44 expression in tumors with severe PTBE (SC II or III) was significantly higher than that in tumors without or with mild PTBE (SC 0 or I). Multivariate logistic regression analysis also revealed that overexpression of CD44 was an independent significant factor of severe PTBE development in primary meningiomas. CONCLUSIONS: In addition to tumor cell aggressiveness, CD44 expression promotes the development of PTBE in meningioma. Since PTBE is a strong factor of tumor-related epilepsy or cognitive dysfunction in patients with meningioma, CD44 is thus a potential therapeutic target in meningioma with PTBE. - BRAF p.V600E変異を有するHigh-grade Gliomaの病理学的研究
京野 里虹; 種井 善一; 伊師 雪友; 小田 義崇; 王 磊; 津田 真寿美; 佐藤 憲市; 寺坂 俊介; 田中 伸哉
日本病理学会会誌, 113, 1, 482, 482, (一社)日本病理学会, 2024年02月
日本語 - Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F-Fluoromisonidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography.
Michinari Okamoto; Shigeru Yamaguchi; Ryosuke Sawaya; Sumire Echizenya; Yukitomo Ishi; Sadahiro Kaneko; Hiroaki Motegi; Takuya Toyonaga; Kenji Hirata; Miki Fujimura
BioMed research international, 2024, 2973407, 2973407, 2024年, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Glioblastoma is the most aggressive primary brain tumor, characterized by its distinctive intratumoral hypoxia. Sequential preoperative examinations using fluorine-18-fluoromisonidazole (18F-FMISO) and fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) could depict the degree of glucose metabolism with hypoxic condition. However, molecular mechanism of glucose metabolism under hypoxia in glioblastoma has been unclear. The aim of this study was to identify the key molecules of hypoxic glucose metabolism. METHODS: Using surgically obtained specimens, gene expressions associated with glucose metabolism were analyzed in patients with glioblastoma (n = 33) who underwent preoperative 18F-FMISO and 18F-FDG PET to identify affected molecules according to hypoxic condition. Tumor in vivo metabolic activities were semiquantitatively evaluated by lesion-normal tissue ratio (LNR). Protein expression was confirmed by immunofluorescence staining. To evaluate prognostic value, relationship between gene expression and overall survival was explored in another independent nonoverlapping clinical cohort (n = 17) and validated by The Cancer Genome Atlas (TCGA) database (n = 167). RESULTS: Among the genes involving glucose metabolic pathway, mRNA expression of glucose-6-phosphatase 3 (G6PC3) correlated with 18F-FDG LNR (P = 0.03). In addition, G6PC3 mRNA expression in 18F-FMISO high-accumulated glioblastomas was significantly higher than that in 18F-FMISO low-accumulated glioblastomas (P < 0.01). Protein expression of G6PC3 was consistent with mRNA expression, which was confirmed by immunofluorescence analysis. These findings indicated that the G6PC3 expression might be facilitated by hypoxic condition in glioblastomas. Next, we investigated the clinical relevance of G6PC3 in terms of prognosis. Among the glioblastoma patients who received gross total resection, mRNA expressions of G6PC3 in the patients with poor prognosis (less than 1-year survival) were significantly higher than that in the patients who survive more than 3 years. Moreover, high mRNA expression of G6PC3 was associated with poor overall survival in glioblastoma, as validated by TCGA database. CONCLUSION: G6PC3 was affluently expressed in glioblastoma tissues with coincidentally high 18F-FDG and 18F-FMISO accumulation. Further, it might work as a prognostic biomarker of glioblastoma. Therefore, G6PC3 is a potential key molecule of glucose metabolism under hypoxia in glioblastoma. - Clinical outcomes for olfactory neuroblastoma.
Akira Nakazono; Hiroaki Motegi; Masanobu Suzuki; Yuji Nakamaru; Shigeru Yamaguchi; Yukitomo Ishi; Satoshi Kano; Nayuta Tsushima; Aya Honma; Takayoshi Suzuki; Shogo Kimura; Seijiro Hamada; Jun Taguchi; Yasushi Shimizu; Takashi Mori; Koichi Yasuda; Hidefumi Aoyama; Ichiro Kinoshita; Miki Fujimura; Akihiro Homma
Frontiers in oncology, 14, 1329572, 1329572, 2024年, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB. METHODS: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data. RESULTS: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS. CONCLUSION: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB. - Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Tomonori Sekizaki; Hiraku Kameda; Akinobu Nakamura; Saki Kuwabara; Hiroshi Nomoto; Kyu Yong Cho; Yukitomo Ishi; Hiroaki Motegi; Hideaki Miyoshi; Tatsuya Atsumi
Pituitary, 26, 5, 597, 610, 2023年10月, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Cushing's disease (CD) results from autonomous adrenocorticotropic hormone (ACTH) secretion by corticotroph adenomas, leading to excessive cortisol production, ultimately affecting morbidity and mortality. Pasireotide is the only FDA approved tumor directed treatment for CD, but it is effective in only about 25% of patients, and is associated with a high rate of hyperglycemia. Neuromedin B (NMB), a member of the bombesin-like peptide family, regulates endocrine secretion and cell proliferation. Here, we assessed NMB and NMB receptor (NMBR) expression in human corticotroph adenomas and the effects of NMBR antagonist PD168368 on murine and human corticotroph tumors. METHODS: To investigate NMB and NMBR expression, real-time qPCR and immunostaining on human pathological specimens of corticotroph, non-functional and somatotroph adenomas were performed. The effects of PD168368 on hormone secretion and cell proliferation were studied in vitro, in vivo and in seven patient-derived corticotroph adenoma cells. NMB and NMBR were expressed in higher extent in human corticotroph adenomas compared with non-functional or somatotroph adenomas. RESULTS: In murine AtT-20 cells, PD168368 reduced proopiomelanocortin (Pomc) mRNA/protein expression and ACTH secretion as well as cell proliferation. In mice with tumor xenografts, tumor growth, ACTH and corticosterone were downregulated by PD168368. In patient-derived adenoma cells, PD168368 reduced POMC mRNA expression in four out of seven cases and ACTH secretion in two out of five cases. A PD168368-mediated cyclin E suppression was also identified in AtT-20 and patient-derived cells. CONCLUSION: NMBR antagonist represents a potential treatment for CD and its effect may be mediated by cyclin E suppression. - Quantitative Evaluations of Vestibular Function in Patients With Petrous Apex Cholesterol Granulomas Treated With an Endoscopic Transsphenoidal Approach: A Report of Two Cases.
Yuuki Fujiwara; Keishi Fujiwara; Hiroaki Motegi; Yukitomo Ishi; Shinya Morita; Kimiko Hoshino; Atsushi Fukuda; Yuji Nakamaru; Akihiro Homma
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 44, 8, 809, 812, 2023年09月01日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: We report two cases of petrous apex cholesterol granuloma (PACG) treated with an endoscopic transsphenoidal approach. Vestibular functions of the two patients were evaluated quantitatively by video Head Impulse Test (vHIT) and/or vestibular evoked myogenic potentials (VEMPs). PATIENTS: Two patients with PACG who experienced episodes of dizziness are presented. INTERVENTION: An endoscopic transsphenoidal approach to PACG. MAIN OUTCOME MEASURE: The preoperative and postoperative vestibular functions as evaluated by vHIT and VEMP. RESULTS: Two cases of PACG were treated by a transsphenoidal approach. The internal auditory canal was compressed by the PACG in both cases. The patients both experienced episodes of dizziness before surgery and preoperative vestibular testing including vHIT and VEMP indicated dysfunction of vestibular nerves. After surgery, their symptoms were completely resolved, and the vestibular testing results were improved. CONCLUSIONS: This article is noteworthy for being the first to publish quantitative vestibular function testing for patients with PACG with vestibular dysfunction. PACG may show various symptoms, with dizziness being one of the most common symptoms. In cases in which the internal auditory canal is compressed by the PACG, vestibular functions should be evaluated by vHIT and VEMP. In the present cases, dizziness was found to be resolved by surgery to release the compression on internal auditory canal. Based on the present cases, the transsphenoidal approach is considered to be both safe and effective. - Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.
Zibo Zhao; Kaixiang Cao; Jun Watanabe; Cassandra N Philips; Jacob M Zeidner; Yukitomo Ishi; Qixuan Wang; Sarah R Gold; Katherine Junkins; Elizabeth T Bartom; Feng Yue; Navdeep S Chandel; Rintaro Hashizume; Issam Ben-Sahra; Ali Shilatifard
The Journal of clinical investigation, 133, 13, 2023年07月03日, [国際誌]
英語, 研究論文(学術雑誌), Epigenetic status-altering mutations in chromatin-modifying enzymes are a feature of human diseases, including many cancers. However, the functional outcomes and cellular dependencies arising from these mutations remain unresolved. In this study, we investigated cellular dependencies, or vulnerabilities, that arise when enhancer function is compromised by loss of the frequently mutated COMPASS family members MLL3 and MLL4. CRISPR dropout screens in MLL3/4-depleted mouse embryonic stem cells (mESCs) revealed synthetic lethality upon suppression of purine and pyrimidine nucleotide synthesis pathways. Consistently, we observed a shift in metabolic activity toward increased purine synthesis in MLL3/4-KO mESCs. These cells also exhibited enhanced sensitivity to the purine synthesis inhibitor lometrexol, which induced a unique gene expression signature. RNA-Seq identified the top MLL3/4 target genes coinciding with suppression of purine metabolism, and tandem mass tag proteomic profiling further confirmed upregulation of purine synthesis in MLL3/4-KO cells. Mechanistically, we demonstrated that compensation by MLL1/COMPASS was underlying these effects. Finally, we demonstrated that tumors with MLL3 and/or MLL4 mutations were highly sensitive to lometrexol in vitro and in vivo, both in culture and in animal models of cancer. Our results depicted a targetable metabolic dependency arising from epigenetic factor deficiency, providing molecular insight to inform therapy for cancers with epigenetic alterations secondary to MLL3/4 COMPASS dysfunction. - GH産生下垂体腺腫でのβ-カテニンの細胞内局在と75g経口ブドウ糖負荷試験におけるGHの奇異性上昇
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
日本内分泌学会雑誌, 99, 1, 332, 332, (一社)日本内分泌学会, 2023年05月
日本語 - GH産生下垂体腺腫でのβ-カテニンの細胞内局在と75g経口ブドウ糖負荷試験におけるGHの奇異性上昇
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
日本内分泌学会雑誌, 99, 1, 332, 332, (一社)日本内分泌学会, 2023年05月
日本語 - AT/RTのEZH2およびBRD4を標的とした新規治療
伊師 雪友; ツァン・ヨンザン; ツァン・アリ; 佐々木 貴浩; 渡邊 潤; 阿部 幸喜; 棗田 学; 山口 秀; 藤村 幹; 橋詰 倫太郎
Brain Tumor Pathology, 40, Suppl., 109, 109, 日本脳腫瘍病理学会, 2023年05月
日本語 - 成長ホルモン産生下垂体腺腫におけるβ-カテニンの細胞内局在と腫瘍径および術後寛解率との関連
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 三好 秀明; 渥美 達也
日本臨床分子医学会学術総会プログラム・抄録集, 58回, 58, 58, 日本臨床分子医学会, 2023年04月
日本語 - 成長ホルモン産生下垂体腺腫におけるβ-カテニンの細胞内局在と腫瘍径および術後寛解率との関連
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 三好 秀明; 渥美 達也
日本臨床分子医学会学術総会プログラム・抄録集, 58回, 58, 58, 日本臨床分子医学会, 2023年04月
日本語 - Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: A case report.
Hiroshi Ikeda; Shigeru Yamaguchi; Yukitomo Ishi; Kento Wakabayashi; Ai Shimizu; Hiromi Kanno-Okada; Takeshi Endo; Mitsutoshi Ota; Michinari Okamoto; Hiroaki Motegi; Norimasa Iwasaki; Miki Fujimura
Neuropathology : official journal of the Japanese Society of Neuropathology, 43, 5, 413, 420, 2023年03月20日, [国際誌]
英語, 研究論文(学術雑誌), Somatic mosaicism of isocitrate dehydrogenase 1/2 (IDH1/2) mutation is a cause of Ollier disease (OD), characterized by multiple enchondromatosis. A 35-year-old woman who was diagnosed with OD at age 24 underwent resection surgery for multifocal tumors located at the right and left frontal lobes that were discovered incidentally. No apparent spatial connection was observed on preoperative magnetic resonance imaging. Pathological examinations revealed tumor cells with a perinuclear halo in the left frontal lobe tumor, whereas astrocytic tumor cells were observed in the right frontal lobe tumor. Based on positive IDH1 R132H immunostaining and the result of 1p/19q fluorescent in situ hybridization, pathological diagnoses were IDH mutant and 1p/19q-codeleted oligodendroglioma in the right frontal lobe tumor and IDH mutant astrocytoma in the left frontal lobe tumor, respectively. The DNA sequencing revealed IDH1 R132H mutation in the peripheral blood sample and frontal lobe tumors. This case suggested that in patients with OD, astrocytoma and oligodendroglioma can co-occur within the same individual simultaneously, and IDH1 R132H mutation was associated with supratentorial development of gliomas. - GH産生下垂体腺腫におけるβ-カテニンの細胞内局在と臨床所見との関連
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
日本内分泌学会雑誌, 98, 5, 1394, 1394, (一社)日本内分泌学会, 2023年03月
日本語 - GH産生下垂体腺腫におけるβ-カテニンの細胞内局在と臨床所見との関連
桑原 咲; 亀田 啓; 野本 博司; 曹 圭龍; 中村 昭伸; 伊師 雪友; 茂木 洋晃; 藤村 幹; 渥美 達也
日本内分泌学会雑誌, 98, 5, 1394, 1394, (一社)日本内分泌学会, 2023年03月
日本語 - Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.
Takahiro Sasaki; Jun Watanabe; Xingyao He; Hiroaki Katagi; Amreena Suri; Yukitomo Ishi; Kouki Abe; Manabu Natsumeda; William H Frey; Peng Zhang; Rintaro Hashizume
Journal of neurosurgery, 138, 6, 1, 10, 2022年11月11日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Diffuse midline gliomas, including diffuse intrinsic pontine gliomas (DIPGs), are among the most malignant and devastating childhood brain cancers. Despite aggressive treatment, nearly all children with these tumors succumb to their disease within 2 years of diagnosis. Due to the anatomical location of the tumors within the pons, surgery is not a treatment option, and distribution of most systematically administered drugs is limited by the blood-brain barrier (BBB). New drug delivery systems that bypass the BBB are desperately needed to improve outcomes of DIPG patients. Intranasal delivery (IND) is a practical and noninvasive drug delivery system that bypasses the BBB and delivers the drugs to the brain through the olfactory and trigeminal neural pathways. In this study, the authors evaluated the efficacy of nanoliposomal (LS) irinotecan (CPT-11) and an active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), using IND in DIPG patient-derived xenograft models. METHODS: In vitro responses to LS-CPT-11 and LS-SN-38 in DIPG cells were evaluated with cell viability, colony formation, and apoptosis assays. The cellular uptakes of rhodamine-PE (Rhod)-labeled LS-CPT-11 and LS-SN-38 were analyzed with fluorescence microscopy. Mice bearing DIPG patient-derived xenografts were treated with IND of LS-control (empty liposome), LS-CPT-11, or LS-SN-38 by IND for 4 weeks. In vivo responses were measured for tumor growth by serial bioluminescence imaging and animal subject survival. The concentration of SN-38 in the brainstem tumor administered by IND was determined by liquid chromatography-mass spectrometry (LC-MS). Immunohistochemical analyses of the proliferative and apoptotic responses of in vivo tumor cells were performed with Ki-67 and TUNEL staining. RESULTS: LS-SN-38 inhibited DIPG cell growth and colony formation and increased apoptosis, outperforming LS-CPT-11. Rhod-labeled LS-SN-38 showed intracellular fluorescence signals beginning at 30 minutes and peaking at 24 hours following treatment. LC-MS analysis revealed an SN-38 concentration in the brainstem tumor of 0.66 ± 0.25 ng/ml (5.43% ± 0.31% of serum concentration). IND of LS-SN-38 delayed tumor growth and significantly prolonged animal survival compared with IND of LS-control (p < 0.0001) and LS-CPT-11 (p = 0.003). IND of LS-SN-38 increased the number of TUNEL-positive cells and decreased the Ki-67-positive cells in the brainstem tumor. CONCLUSIONS: This study demonstrates that IND of LS-SN-38 bypasses the BBB and enables efficient and noninvasive drug delivery to the brainstem tumor, providing a promising therapeutic approach for treating DIPG. - Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Guisheng Zhao; Patrick Newbury; Yukitomo Ishi; Eugene Chekalin; Billy Zeng; Benjamin S Glicksberg; Anita Wen; Shreya Paithankar; Takahiro Sasaki; Amreena Suri; Javad Nazarian; Michael E Pacold; Daniel J Brat; Theodore Nicolaides; Bin Chen; Rintaro Hashizume
Acta neuropathologica communications, 10, 1, 150, 150, 2022年10月23日, [国際誌]
英語, 研究論文(学術雑誌), Diffuse intrinsic pontine glioma (DIPG) is an aggressive incurable brainstem tumor that targets young children. Complete resection is not possible, and chemotherapy and radiotherapy are currently only palliative. This study aimed to identify potential therapeutic agents using a computational pipeline to perform an in silico screen for novel drugs. We then tested the identified drugs against a panel of patient-derived DIPG cell lines. Using a systematic computational approach with publicly available databases of gene signature in DIPG patients and cancer cell lines treated with a library of clinically available drugs, we identified drug hits with the ability to reverse a DIPG gene signature to one that matches normal tissue background. The biological and molecular effects of drug treatment was analyzed by cell viability assay and RNA sequence. In vivo DIPG mouse model survival studies were also conducted. As a result, two of three identified drugs showed potency against the DIPG cell lines Triptolide and mycophenolate mofetil (MMF) demonstrated significant inhibition of cell viability in DIPG cell lines. Guanosine rescued reduced cell viability induced by MMF. In vivo, MMF treatment significantly inhibited tumor growth in subcutaneous xenograft mice models. In conclusion, we identified clinically available drugs with the ability to reverse DIPG gene signatures and anti-DIPG activity in vitro and in vivo. This novel approach can repurpose drugs and significantly decrease the cost and time normally required in drug discovery. - Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset.
Shigeru Yamaguchi; Michinari Okamoto; Yukitomo Ishi; Ryosuke Sawaya; Hiroaki Motegi; Minako Sugiyama; Taisuke Harada; Noriyuki Fujima; Takashi Mori; Takayuki Hashimoto; Emi Takakuwa; Atsushi Manabe; Kohsuke Kudo; Hidefumi Aoyama; Miki Fujimura
Journal of neurosurgery. Pediatrics, 1, 8, 2022年09月09日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. METHODS: The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. RESULTS: Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. CONCLUSIONS: End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases. - A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
Yusuke Tomita; Yosuke Shimazu; Agila Somasundaram; Yoshihiro Tanaka; Nozomu Takata; Yukitomo Ishi; Samantha Gadd; Rintaro Hashizume; Angelo Angione; Gonzalo Pinero; Dolores Hambardzumyan; Daniel J Brat; Christine M Hoeman; Oren J Becher
Glia, 70, 9, 1681, 1698, 2022年05月07日, [国際誌]
英語, 研究論文(学術雑誌), Diffuse midline glioma (DMG) is a type of lethal brain tumor that develops mainly in children. The majority of DMG harbor the K27M mutation in histone H3. Oligodendrocyte progenitor cells (OPCs) in the brainstem are candidate cells-of-origin for DMG, yet there is no genetically engineered mouse model of DMG initiated in OPCs. Here, we used the RCAS/Tv-a avian retroviral system to generate DMG in Olig2-expressing progenitors and Nestin-expressing progenitors in the neonatal mouse brainstem. PDGF-A or PDGF-B overexpression, along with p53 deletion, resulted in gliomas in both models. Exogenous overexpression of H3.3K27M had a significant effect on tumor latency and tumor cell proliferation when compared with H3.3WT in Nestin+ cells but not in Olig2+ cells. Further, the fraction of H3.3K27M-positive cells was significantly lower in DMGs initiated in Olig2+ cells relative to Nestin+ cells, both in PDGF-A and PDGF-B-driven models, suggesting that the requirement for H3.3K27M is reduced when tumorigenesis is initiated in Olig2+ cells. RNA-sequencing analysis revealed that the differentially expressed genes in H3.3K27M tumors were non-overlapping between Olig2;PDGF-B, Olig2;PDGF-A, and Nestin;PDGF-A models. GSEA analysis of PDGFA tumors confirmed that the transcriptomal effects of H3.3K27M are cell-of-origin dependent with H3.3K27M promoting epithelial-to-mesenchymal transition (EMT) and angiogenesis when Olig2 marks the cell-of-origin and inhibiting EMT and angiogenesis when Nestin marks the cell-of-origin. We did observe some overlap with H3.3K27M promoting negative enrichment of TNFA_Signaling_Via_NFKB in both models. Our study suggests that the tumorigenic effects of H3.3K27M are cell-of-origin dependent, with H3.3K27M being more oncogenic in Nestin+ cells than Olig2+ cells. - Machine learning for rhabdomyosarcoma histopathology.
Arthur O Frankel; Melvin Lathara; Celine Y Shaw; Owen Wogmon; Jacob M Jackson; Mattie M Clark; Navah Eshraghi; Stephanie E Keenen; Andrew D Woods; Reshma Purohit; Yukitomo Ishi; Nirupama Moran; Mariko Eguchi; Farhat Ul Ain Ahmed; Sara Khan; Maria Ioannou; Konstantinos Perivoliotis; Pin Li; Huixia Zhou; Ahmad Alkhaledi; Elizabeth J Davis; Danielle Galipeau; R Lor Randall; Agnieszka Wozniak; Patrick Schoffski; Jerry Lee; Paul H Huang; Robin L Jones; Brian P Rubin; Morgan Darrow; Ganapati Srinivasa; Erin R Rudzinski; Sonja Chen; Noah E Berlow; Charles Keller
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022年04月21日, [国際誌]
英語, 研究論文(学術雑誌), Correctly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the correct treatment regimen. With a finite number of pathologists worldwide specializing in pediatric/young adult sarcoma histopathology, access to expert differential diagnosis early in case assessment is limited for many global regions. The lack of highly-trained sarcoma pathologists is especially pronounced in low to middle-income countries, where pathology expertise may be limited despite a similar rate of sarcoma incidence. To address this issue in part, we developed a deep learning convolutional neural network (CNN)-based differential diagnosis system to act as a pre-pathologist screening tool that quantifies diagnosis likelihood amongst trained soft-tissue sarcoma subtypes based on whole histopathology tissue slides. The CNN model is trained on a cohort of 424 centrally-reviewed histopathology tissue slides of alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma and clear-cell sarcoma tumors, all initially diagnosed at the originating institution and subsequently validated by central review. This CNN model was able to accurately classify the withheld testing cohort with resulting receiver operating characteristic (ROC) area under curve (AUC) values above 0.889 for all tested sarcoma subtypes. We subsequently used the CNN model to classify an externally-sourced cohort of human alveolar and embryonal rhabdomyosarcoma samples and a cohort of 318 histopathology tissue sections from genetically engineered mouse models of rhabdomyosarcoma. Finally, we investigated the overall robustness of the trained CNN model with respect to histopathological variations such as anaplasia, and classification outcomes on histopathology slides from untrained disease models. Overall positive results from our validation studies coupled with the limited worldwide availability of sarcoma pathology expertise suggests the potential of machine learning to assist local pathologists in quickly narrowing the differential diagnosis of sarcoma subtype in children, adolescents, and young adults. - Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
Yukitomo Ishi; Shigeru Yamaguchi; Michinari Okamoto; Ryosuke Sawaya; Shogo Endo; Hiroaki Motegi; Shunsuke Terasaka; Zen-Ichi Tanei; Kanako C Hatanaka; Shinya Tanaka; Miki Fujimura
Brain tumor pathology, 39, 3, 162, 170, 2022年04月01日, [国内誌]
英語, 研究論文(学術雑誌), The aim of this study was to analyze the clinical and radiological characteristics of glioblastomas (GBMs) harboring a BRAF mutation. Sequencing analysis of BRAF, IDH1/2, and TERT promoters was performed on GBM samples of patients older than 15 years. The clinical, pathological, and radiological data of patients were retrospectively reviewed. Patients were classified into three groups according to their BRAF and IDH1/2 status: BRAF group, IDH group, and BRAF/IDH-wild-type (WT) group. Among 179 GBM cases, we identified nine cases with a BRAF mutation and nine with IDH mutation. The WT group had 161 cases. Age at onset in the BRAF group was significantly lower compared to the WT group and was similar to the IDH group. In cases with negative IDH1-R132H staining and age < 55 years, 15.2% were BRAF-mutant cases. Similar to the IDH group, overall survival of the BRAF group was significantly longer compared with the WT group. Among nine cases in the BRAF group, three cases had hemorrhagic onset and prior lesions were observed in two cases. In conclusion, age < 55 years, being IDH1-R132H negative, with hemorrhagic onset or the presence of prior lesions are factors that signal recommendation of BRAF analysis for adult GBM patients. - Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.
Yukitomo Ishi; Yongzhan Zhang; Ali Zhang; Takahiro Sasaki; Andrea Piunti; Amreena Suri; Jun Watanabe; Kouki Abe; Xingyao He; Hiroaki Katagi; Pankaj Bhalla; Manabu Natsumeda; Lihua Zou; Ali Shilatifard; Rintaro Hashizume
Molecular cancer therapeutics, 2022年02月28日, [国際誌]
英語, 研究論文(学術雑誌), Aberrant activity of the H3K27 modifiers EZH2 and BRD4 is an important oncogenic driver for atypical teratoid/rhabdoid tumor (AT/RT), and each is potentially a possible therapeutic target for treating AT/RT. We therefore determined whether targeting distinct histone modifier activities was an effective approach for treating AT/RT. The effects of EZH2 and BRD4 inhibition on histone modification, cell proliferation, and cell invasion were analyzed by immunoblotting, MTS assay, colony formation assay, and cell invasion assay. RNA- and chromatin immunoprecipitation-sequencing were used to determine transcriptional and epigenetic changes in AT/RT cells treated with EZH2 and BRD4 inhibitors. We treated mice bearing human AT/RT xenografts with EZH2 and BRD4 inhibitors. Intracranial tumor growth was monitored by bioluminescence imaging, and the therapeutic response was evaluated by animal survival. AT/RT cells showed elevated levels of H3K27 trimethylation (H3K27me3) and H3K27 acetylation (H3K27ac), with expression of EZH2 and BRD4, and lack of SMARCB1 proteins. Targeted inhibition of EZH2 and BRD4 activities reduced cell proliferation and invasiveness of AT/RT in association with decreasing H3K27me3 and H3K27ac. Differential genomic occupancy of H3K27me3 and H3K27ac regulated specific gene expression in response to EZH2 and BRD4 inhibitions. A combination of EZH2 and BRD4 inhibition increased the therapeutic benefit in vitro and in vivo, outperforming either monotherapy. Overall, histone H3K27me3 and H3K27ac were elevated in AT/RT cells and distributed in distinct chromatin regions to regulate specific gene expression and to promote AT/RT growth. Targeting EZH2 and BRD4 activity is therefore a potential combination therapy for AT/RT. - Analysis of induced pluripotent stem cell clones derived from a patient with mosaic neurofibromatosis type 2.
Yukitomo Ishi; Takumi Era; Sayaka Yuzawa; Michinari Okamoto; Ryosuke Sawaya; Hiroaki Motegi; Shigeru Yamaguchi; Shunsuke Terasaka; Kiyohiro Houkin; Miki Fujimura
American journal of medical genetics. Part A, 2022年02月18日, [国際誌]
英語, The diagnosis of mosaicism is challenging in patients with neurofibromatosis type 2 (NF2) subset due to low variant allele frequency. In this study, we generated induced pluripotent stem cells (iPSCs) were generated from a patient clinically diagnosed with NF2 based on multiple schwannomas, including bilateral vestibular schwannomas and meningiomas. Genetic analysis of the patient's mononuclear cells (MNCs) from peripheral blood failed to detect NF2 alteration but successfully found p.Q65X (c.193C>T) mutation in all separate tumors with three intracranial meningiomas and one intraorbital schwannoma, and confirming mosaicism diagnosis in NF2 alteration using deep sequencing. Five different clones with patient-derived iPSCs were established from MNCs in peripheral blood, which showed sufficient expression of pluripotent markers. Genetic analysis showed that one of five generated iPSC lines from MNCs had the same p.Q65X mutation as that found in NF2. There was no significant difference in the expression of genes related to NF2 between iPSC clones with the wild-type and mutant NF2. In this case, clonal expansion of mononuclear bone marrow-derived stem cells recapitulated mosaicism's genetic alteration in NF2. Patient-derived iPSCs from mosaic NF2 would contribute to further functional research of NF2 alteration. - Cystic Intracranial Recurrence of Olfactory Neuroblastoma without Accumulation on Fluorine-18-fluorodeoxyglucose Positron Emission Tomography.
Yukitomo Ishi; Shigeru Yamaguchi; Kanako C Hatanaka; Emi Takakuwa; Hiroaki Motegi; Taishi Honda; Hiroyuki Kobayashi; Shunsuke Terasaka; Akihiro Homma; Miki Fujimura; Kiyohiro Houkin
Acta medica Okayama, 76, 1, 93, 98, 2022年02月, [国内誌]
英語, A 66-year-old man underwent multimodal treatment for olfactory neuroblastoma (ONB). When he was 72 years old, a cystic intracranial lesion without accumulation on fluorine-18-fluorodeoxyglucose positron emission tomography was detected. Surgical resection was performed when the patient was 73 years old. The pathological examination revealed recurrence of ONB, and the patient underwent focal irradiation. At age 81, he presented with a second recurrence in the right occipital lobe with radiological and pathological findings similar to the prior recurrence. This case suggests that pathological confirmation should be considered in cases with atypical radiological findings following the treatment of ONB. - DEVELOPMENT OF NOVEL HISTONE DEMETHYLASE INHIBITOR AGAINST DIPG
Yukitomo Ishi
Neuro-Oncology, 2022年
研究論文(学術雑誌) - RADIOSENSITIZATION BY BRD4 INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA
Yukitomo Ishi
Neuro-Oncology, 2022年
研究論文(学術雑誌) - Detection of the Moment of Nerve Decompression Using Continuous Monitoring of Evoked Facial Nerve Electromyograms in a Patient with Facial Nerve Schwannoma: Case Report.
Asuka Nakazaki; Shigeru Yamaguchi; Hiroaki Motegi; Yukitomo Ishi; Michinari Okamoto; Miki Fujimura
NMC case report journal, 9, 213, 216, 2022年, [国内誌]
英語, Facial nerve function improvement is a challenging goal in facial nerve schwannoma (FNS) surgery. Intraoperative continuous monitoring of evoked facial nerve electromyograms (CFN-EMGs) is performed in acoustic neuroma surgery to preserve facial nerve function. CFN-EMGs were applied in decompression surgery for FNS with severe facial paresis. A 39-year-old woman presented with a sudden onset of vertigo, left hearing disturbance, and severe left facial palsy with House-Brackmann (HB) grade 5. FNS was strongly suspected based on the patient's clinical course and magnetic resonance imaging findings, and the patient underwent surgical decompression of the internal auditory canal (IAC) to improve facial nerve function 9 weeks after onset. CFN-EMG responses suddenly improved after removing the posterior wall of the IAC and incising its dura matter. Since the patient's facial nerve paresis improved to HB grade 2 after surgery, CFN-EMGs could detect the moment of facial nerve decompression. This would be the first report to show that CFN-EMGs applied in decompression surgery for FNS could detect the effects of decompression during surgery in real-time. Thus, CFN-EMGs may be an effective monitoring method in decompression surgery for FNS. - Successful Treatment of Intracranial Methotrexate-associated Lymphoproliferative Disorder without Epstein-Barr Virus Infection Using Rituximab, Methotrexate, Procarbazine, and Vincristine: A Case Report.
Makoto Mizushima; Yukitomo Ishi; Hiroshi Ikeda; Ikuma Echizenya; Takuya Otsuka; Tomoko Mitsuhashi; Shigeru Yamaguchi; Miki Fujimura
NMC case report journal, 9, 237, 242, 2022年, [国内誌]
英語, Methotrexate-associated lymphoproliferative disorder (MTX-LPD) occurs in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX). MTX-LPD is typically associated with Epstein-Barr virus (EBV) infection and regresses with MTX discontinuation. On the other hand, EBV-negative MTX-LPDs are less common and are more likely to show partial or no regression after MTX discontinuation. There were no standard chemotherapeutic options for refractory MTX-LPD. We present a case of EBV-negative MTX-LPD in the central nervous system (CNS) that was successfully treated with rituximab, methotrexate, procarbazine, and vincristine (R-MPV), followed by reduced-dose whole-brain radiotherapy (rdWBRT), following the same treatment protocol as primary CNS lymphoma. A 59-year-old woman with RA treated with MTX presented with gradually developing staggered gait, memory deficit, and disorientation. Multiple lesions with heterogeneous contrast enhancement were discovered using brain magnetic resonance imaging. The patient was suspected of having MTX-LPD, but discontinuing MTX did not result in regression of the brain lesions. She underwent a biopsy from the left parietal lesion. The tissue was pathologically diagnosed as diffuse large B-cell lymphoma. Furthermore, pathological examination through EBV-encoded ribonucleic acid in situ hybridization demonstrated a lack of EBV infection. She was ultimately diagnosed with EBV-negative CNS MTX-LPD. We applied chemotherapy with R-MPV and rdWBRT. The patient achieved a complete response. In the case of CNS MTX-LPD without EBV infection, chemotherapy with R-MPV followed by rdWBRT may be considered. - The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma
Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Michinari Okamoto; Hiroyuki Kobayashi; Kenji Hirata; Yoshitaka Oda; Shinya Tanaka; Shunsuke Terasaka; Kiyohiro Houkin
Journal of Neurosurgical Sciences, 64, 6, 502, 508, Edizioni Minerva Medica, 2021年12月01日
英語, 研究論文(学術雑誌) - Variations and natural history of primary intraparenchymal lesions associated with neurofibromatosis type 2.
Yukitomo Ishi; Taisuke Harada; Hiroyuki Kameda; Hiromi Okada; Isao Yokota; Michinari Okamoto; Ryosuke Sawaya; Hiroaki Motegi; Shigeru Yamaguchi; Shunsuke Terasaka; Kohsuke Kudo; Miki Fujimura
Neuroradiology, 64, 2, 393, 396, 2021年11月23日, [国際誌]
英語, 研究論文(学術雑誌), The study aimed to investigate the clinical implications and natural history of primary intraparenchymal lesions in patients with neurofibromatosis type 2. Radiological findings of 15 neurofibromatosis type 2 cases were retrospectively collected. Twenty-seven primary intraparenchymal lesions were observed in 7 out of 15 patients (47%). Cortical/subcortical T2 hyperintense lesions and enlarged Virchow-Robin spaces were the most common findings in five and four patients, respectively. During the follow-up period (median 84 months), one new primary intraparenchymal lesion was identified and increased lesions were observed in two cases on contrast-enhanced MRI. Surgical resection was performed in one case pathologically diagnosed with atypical meningioma. Twenty-five other lesions without contrast enhancement presented no apparent growth during follow-up. Although most primary intraparenchymal lesions are benign, a subset of cases would present newly developed or increased lesions on contrast-enhanced MRI. Careful monitoring is necessary for such cases, and pathological confirmation should be considered. - Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion.
Minako Sugiyama; Shinsuke Hirabayashi; Yukitomo Ishi; Junko Kikuchi; Ayako Ishikura; Hiroaki Motegi; Yuki Ueda; Saori Sawai; Kazuya Hara; Yukayo Terashita; Yuko Cho; Emi Takakuwa; Shohei Honda; Shigeru Yamaguchi; Ichiro Kinoshita; Atsushi Manabe
Pediatric blood & cancer, 68, 11, e29227, 2021年07月10日, [国際誌]
英語 - Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Yukitomo Ishi; Hiromi Okada; Michinari Okamoto; Hiroaki Motegi; Shinya Tanaka; Tomoko Mitsuhashi; Shigeru Yamaguchi
Neuropathology : official journal of the Japanese Society of Neuropathology, 41, 3, 236, 242, 2021年06月, [国際誌]
英語, The majority of oligodendroglial tumors harbor mutations in the telomerase reverse transcriptase (TERT) gene (TERT) promoter and the isocitrate dehydrogenase 1/2 (IDH1/2) gene (IDH1/2), as well as 1p/19q codeletion. Generally, TERT promoter mutations, C250T and C228T, are mutually exclusive. We present a case of oligodendroglioma harboring both C250T and C228T mutations in TERT promoter. A 38-year-old man presented with grand mal seizures and underwent a resection surgery for a left frontal lobe tumor. He was pathologically diagnosed as having oligodendroglioma and was carefully observed. At 48 years of age, he underwent another resection surgery due to tumor regrowth, with the pathological diagnosis of anaplastic oligodendroglioma. Genetic analysis of the initial tumor specimen revealed IDH1 R132H mutation and both C250T and C228T mutations in TERT promoter. Using mutation-specific primers, two mutations were considered to be distributed in different alleles. In the tumor specimen obtained during the second surgery, IDH1 R132H mutation was detected to be similar to that of the initial specimen; however, only C228T mutation was detected in TERT promoter. The 1p/19q codeletion was detected in both the initial and recurrent tumor specimens. According to the sequencing data from the two tumor specimens, although TERT promoter mutation has been considered to be an early genetic event in the tumorigenesis of oligodendroglial tumors, it is likely that the C250T and C228T mutations in TERT promoter are subclonally distributed in the same tumor specimen of the present case. - Ollier病に合併した多発神経膠腫の一例
池田 寛; 山口 秀; 伊師 雪友; 若林 健人; 清水 亜衣; 岡本 迪成; 茂木 洋晃; 藤村 幹
Brain Tumor Pathology, 38, Suppl., 079, 079, 日本脳腫瘍病理学会, 2021年05月
日本語 - ニューロメジンB受容体はACTH産生下垂体腺腫の治療ターゲットとなりうる
関崎 知紀; 亀田 啓; 中村 昭伸; 野本 博司; 曹 圭龍; 伊師 雪友; 茂木 洋晃; 三好 秀明; 渥美 達也
日本内分泌学会雑誌, 97, 1, 261, 261, (一社)日本内分泌学会, 2021年04月
日本語 - High-grade neuroepithelial tumor with BCL6 corepressor-alteration presenting pathological and radiological calcification: A case report.
Yukitomo Ishi; Ai Shimizu; Emi Takakuwa; Minako Sugiyama; Michinari Okamoto; Hiroaki Motegi; Shinsuke Hirabayashi; Yuko Cho; Akihiro Iguchi; Atsushi Manabe; Sumihito Nobusawa; Shinya Tanaka; Shigeru Yamaguchi
Pathology international, 71, 5, 348, 354, 2021年03月13日, [国際誌]
英語, A 5-year-old girl presented with headache and vomiting. Head computed tomography and magnetic resonance imaging showed a right frontal lobe tumor with marked calcification. The patient underwent resection surgery with suspicion of anaplastic ependymoma, and the tumor was gross totally removed. Pathological examination revealed areas of dense tumor cells with a high nucleocytoplasmic ratio and myxoid areas consisting of tumor cells with a round-shaped nucleus and eosinophilic cytoplasm. Perivascular pseudorosette, necrosis, circumscribed growth, and microcalcification were also observed. Immunohistochemistry demonstrated negative staining for glial fibrillary protein and epithelial membrane antigen. Diagnosis of a high-grade neuroepithelial tumor (HGNET) with BCL6 corepressor (BCOR) alteration was made based on pathological findings and internal tandem duplication in the exon 15 of BCOR. Although calcification on radiological and pathological examination is not typical, it would be essential to recognize that calcification could appear in HGNET-BCOR. - Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis.
Shigeru Yamaguchi; Hiroaki Motegi; Yukitomo Ishi; Michinari Okamoto; Ryosuke Sawaya; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
Neurologia medico-chirurgica, 61, 4, 245, 252, 2021年03月04日, [国内誌]
英語, 研究論文(学術雑誌), Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospectively analyzed the treatment outcomes of 124 patients with recurrent GBM who were initially treated with the Stupp protocol between 2006 and 2019. Given that BEV has only been available in Japan since 2013, we grouped the patients into two groups according to the time of first recurrence: the pre-BEV group (N = 51) included patients who had recurrence before BEV approval, and the BEV group (N = 73) included patients with recurrence after BEV approval. The overall survival after first recurrence (OS-R) was analyzed according to the treatment strategy. Among 124 patients, 27 patients (19.4%) received cytoreductive surgery. There were nine cases in the pre-BEV group and 18 cases in the BEV group. Although the mean extent of resection for both groups was almost equal, OS-R was significantly different. The median OS-R was 8.1 m in the pre-BEV group and 16.3 m in the BEV group (P = 0.007). Multivariate analysis revealed that the unavailability of BEV postoperatively (P = 0.03) and decreasing performance status by surgery (P = 0.01) were significant poor prognostic factors for survival after surgery. With the advent of BEV, cytoreductive surgery might provide superior survival benefit at the time of GBM recurrence, especially in cases where surgery can be performed without deteriorating the patient's condition. - Novel risk factors and management of brain sag after brain tumor surgery
Motegi H; Yamaguchi S; Okamoto M; Ishi Y; Endo S; Kaneko S; Kobayashi H; Terasaka S; Houkin K
Interdisciplinary Neurosurgery, 23, 100951, 2021年03月, [査読有り]
英語, 研究論文(学術雑誌) - Use of magnetic resonance venography for inferior petrosal sinus sampling.
Kikutaro Tokairin; Toshiya Osanai; Noriyuki Fujima; Kinya Ishizaka; Hiroaki Motegi; Yukitomo Ishi; Hiraku Kameda; Taku Sugiyama; Ken Kazumata; Naoki Nakayama
The journal of vascular access, 23, 3, 1129729821997263, 1129729821997263, 2021年02月24日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Inferior petrosal sinus (IPS) sampling (IPSS) is a transvenous interventional procedure performed to diagnose Cushing's disease. The reported IPSS failure rate is approximately 10% because IPS catheter delivery is conducted blindly and is challenging because of IPS anatomical variations. This study aimed to evaluate the usefulness of preprocedural magnetic resonance venography (MRV) for assessing IPS access routes before IPSS. METHODS: Nineteen consecutive patients who underwent IPSS at a single university hospital in Japan were retrospectively studied. A preprocedural MRV protocol optimized to visualize the IPS before IPSS was established and utilized in the eight most recent cases. An IPSS procedure was considered successful when bilateral IPS catheterization was accomplished. Patient demographics, IPSS success rate, and radiation dose required during IPSS were compared between two groups: MRV group (N = 8) and no-MRV group (N = 11) before IPSS. RESULTS: There were no significant differences in age, sex, and IPSS success rates between the groups. The average radiation dose was 663.6 ± 246.8 (SD) mGy and 981.7 ± 389.5 (SD) mGy in the MRV group and no-MRV group, respectively. Thus, there was a significant reduction in radiation exposure in the MRV group (p = 0.044). Catheterization of the left IPS was unsuccessful in only one patient in the MRV group owing to IPS hypoplasty, as found on the MRV. CONCLUSIONS: Hypoplastic IPSs occur in patients and can complicate IPSS. Preprocedural MRV assessment is useful for understanding venous anatomy and preventing unnecessary intravenous catheter manipulation during IPSS, which involves blind manipulation around the IPS. - Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.
Ran Tomomasa; Yasuhito Arai; Reika Kawabata-Iwakawa; Kohei Fukuoka; Yoshiko Nakano; Natsuko Hama; Satoshi Nakata; Nozomi Suzuki; Yukitomo Ishi; Shinya Tanaka; Jun A Takahashi; Yoshiaki Yuba; Mitsutaka Shiota; Atsushi Natsume; Michihiro Kurimoto; Yoshiki Shiba; Mikiko Aoki; Kazuki Nabeshima; Toshiyuki Enomoto; Tooru Inoue; Junya Fujimura; Akihide Kondo; Takashi Yao; Naoki Okura; Takanori Hirose; Atsushi Sasaki; Masahiko Nishiyama; Koichi Ichimura; Tatsuhiro Shibata; Junko Hirato; Hideaki Yokoo; Sumihito Nobusawa
Brain pathology (Zurich, Switzerland), 31, 3, e12943, 2021年02月12日, [国際誌]
英語, 研究論文(学術雑誌), Recurrent fusion genes involving C11orf95, C11orf95-RELA, have been identified only in supratentorial ependymomas among primary CNS tumors. Here, we report hitherto histopathologically unclassifiable high-grade tumors, under the tentative label of "ependymoma-like tumors with mesenchymal differentiation (ELTMDs)," harboring C11orf95-NCOA1/2 or -RELA fusion. We examined the clinicopathological and molecular features in five cases of ELTMDs. Except for one adult case (50 years old), all cases were in children ranging from 1 to 2.5 years old. All patients presented with a mass lesion in the cerebral hemisphere. Histologically, all cases demonstrated a similar histology with a mixture of components. The major components were embryonal-appearing components forming well-delineated tumor cell nests composed of small uniform cells with high proliferative activity, and spindle-cell mesenchymal components with a low- to high-grade sarcoma-like appearance. The embryonal-appearing components exhibited minimal ependymal differentiation including a characteristic EMA positivity and tubular structures, but histologically did not fit with ependymoma because they lacked perivascular pseudorosettes, a histological hallmark of ependymoma, formed well-delineated nests, and had diffuse and strong staining for CAM5.2. Molecular analysis identified C11orf95-NCOA1, -NCOA2, and -RELA in two, one, and two cases, respectively. t-distributed stochastic neighbor embedding analysis of DNA methylation data from two cases with C11orf95-NCOA1 or -NCOA2 and a reference set of 380 CNS tumors revealed that these two cases were clustered together and were distinct from all subgroups of ependymomas. In conclusion, although ELTMDs exhibited morphological and genetic associations with supratentorial ependymoma with C11orf95-RELA, they cannot be regarded as ependymoma. Further analyses of more cases are needed to clarify their differences and similarities. - INITIAL MANAGEMENT OF HYDROCEPHALUS IN THE PEDIATRIC AND YOUNG-ADULT PATIENTS WITH BRAIN TUMORS; THE EFFICACY OF LONG-TERM INDWELLING EXTERNAL VENTRICULAR DRAINAGE
Shigeru Yamaguchi; Hiroaki Motegi; Yukitomo Ishi; Michinari Okamoto; Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Atushi Manabe; Kiyohiro Houkin
NEURO-ONCOLOGY, 22, 461, 461, 2020年12月, [査読有り]
英語 - DIAGNOSTIC CAPABILITY OF CSF-PLAP ON INTRACRANIAL GERM CELL TUMOR
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Yuko Cho; Akihiro Iguchi; Atushi Manabe; Kiyohiro Houkin
NEURO-ONCOLOGY, 22, 334, 334, 2020年12月, [査読有り]
英語 - CAN HIGH LEVEL SERUM HCG-B BE CONSIDERED EQUIVALENT TO A DIAGNOSIS OF CHORIOCARCINOMA IN PRIMARY CENTRAL NERVOUS SYSTEM GERM-CELL TUMOR?
Hiroaki Motegi; Shigeru Yamaguchi; Yukitomo Ishi; Michinari Okamoto; Akihiro Iguchi; Yuko Cho; Minako Sugiyama; Atsushi Manabe; Kiyohiro Houkin
NEURO-ONCOLOGY, 22, 329, 330, 2020年12月, [査読有り]
英語 - TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Hideyuki Arita; Yuko Matsushita; Ryunosuke Machida; Kai Yamasaki; Nobuhiro Hata; Makoto Ohno; Shigeru Yamaguchi; Takashi Sasayama; Shota Tanaka; Fumi Higuchi; Toshihiko Iuchi; Kuniaki Saito; Masayuki Kanamori; Ken-Ichiro Matsuda; Yohei Miyake; Kaoru Tamura; Sho Tamai; Taishi Nakamura; Takehiro Uda; Yoshiko Okita; Junya Fukai; Daisuke Sakamoto; Yasuhiko Hattori; Eriel Sandika Pareira; Ryusuke Hatae; Yukitomo Ishi; Yasuji Miyakita; Kazuhiro Tanaka; Shunsaku Takayanagi; Ryohei Otani; Tsukasa Sakaida; Keiichi Kobayashi; Ryuta Saito; Kazuhiko Kurozumi; Tomoko Shofuda; Masahiro Nonaka; Hiroyoshi Suzuki; Makoto Shibuya; Takashi Komori; Hikaru Sasaki; Masahiro Mizoguchi; Haruhiko Kishima; Mitsutoshi Nakada; Yukihiko Sonoda; Teiji Tominaga; Motoo Nagane; Ryo Nishikawa; Yonehiro Kanemura; Aya Kuchiba; Yoshitaka Narita; Koichi Ichimura
Acta neuropathologica communications, 8, 1, 201, 201, 2020年11月23日, [国際誌]
英語, 研究論文(学術雑誌), TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of TERT promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both TERT promoter mutation and 1p/19q codeletion, while 30 had either TERT promoter mutation (n = 24) or 1p/19q codeletion (n = 6) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, TERT promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90-100%) were associated with favorable prognosis (p < 0.05). A multivariable Cox regression model revealed that TERT promoter mutation had a significantly favorable prognostic impact (hazard ratio = 0.421, p = 0.049), while 1p/19q codeletion did not have a significant impact (hazard ratio = 0.648, p = 0.349). Analyses incorporating patient clinical and genetic information were further conducted to identify subgroups showing the favorable prognostic impact of TERT promoter mutation. Among the grade II-III glioma patients with a KPS score of 90 or 100, those with IDH-TERT co-mutation and intact 1p/19q (n = 17) showed significantly longer survival than those with IDH mutation, wild-type TERT, and intact 1p/19q (n = 185) (5-year overall survival, 94% and 77%, respectively; p = 0.032). Our results demonstrate that TERT promoter mutation predicts favorable prognosis independent of 1p/19q codeletion in IDH-mutated gliomas. Combined with its adverse effect on survival among IDH-wild glioma cases, the bivalent prognostic impact of TERT promoter mutation may help further refine the molecular diagnosis and prognostication of diffuse gliomas. - Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Takashi Mori; Takayuki Hashimoto; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Akihiro Iguchi; Yuko Cho; Atsushi Manabe; Kiyohiro Houkin
Oncology, 99, 1, 1, 9, 2020年09月09日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors. - Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.
Yukitomo Ishi; Soichiro Takamiya; Toshitaka Seki; Kazuyoshi Yamazaki; Kazutoshi Hida; Kanako C Hatanaka; Yusuke Ishida; Yoshitaka Oda; Shinya Tanaka; Shigeru Yamaguchi
Brain tumor pathology, 37, 3, 81, 88, 2020年07月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), The objective of this study is to clarify clinical significance of the H3F3A K27M mutation (H3K27M) and analyze the correlation between H3K27M, H3K27me3 status, and EZH2 expression and prognosis in spinal cord gliomas. Patients with spinal cord diffuse glioma regardless of World Health Organization (WHO) grade underwent genetic analysis for H3F3A, HIST1H3B, TERT promoter, IDH1/2, and BRAF. H3K27me3 status and EZH2 expression were analyzed through immunohistochemistry. Thereafter, the association between H3K27M, H3K27me3 status, and EZH2 expression and prognosis was retrospectively analyzed using the log-rank test. A total of 26 cases, 5 with WHO grade 4, 9 with grade 3, and 12 with grade 2 glioma, were analyzed. Although WHO grade 2 cases tended to present favorable overall survival, the difference was not statistically significant. H3K27M, which was detected in four grade 4 cases (80%) and three grade 3 cases (33%), was not associated with prognosis among grade 3 and 4 cases. Among WHO grade 2-4 cases, the combination of retained H3K27me3 and negative EZH2 expression was correlated with favorable overall survival (p = 0.03). The combination of H3K27me3 status and EZH2 expression was considered as a potential prognostic marker in WHO grade 2-4 diffuse spinal cord gliomas. - Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients.
Yukitomo Ishi; Shigeru Yamaguchi; Kanako C Hatanaka; Michinari Okamoto; Hiroaki Motegi; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
Journal of neurosurgery, 134, 3, 1, 9, 2020年02月14日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: The authors aimed to investigate genetic alterations in low-grade gliomas (LGGs) in pediatric and young adult patients presenting with spontaneous hemorrhage. METHODS: Patients younger than 30 years of age with a pathological diagnosis of World Health Organization (WHO) grade I or II glioma and who had undergone treatment at the authors' institution were retrospectively examined. BRAF V600E, FGFR1 N546/K656, IDH1 R132, IDH2 R172, and KIAA1549-BRAF (K-B) fusion genetic alterations were identified, and the presence of spontaneous tumoral hemorrhage was recorded. RESULTS: Among 66 patients (39 with WHO grade I and 27 with grade II tumors), genetic analysis revealed K-B fusion in 18 (27.3%), BRAF V600E mutation in 14 (21.2%), IDH1/2 mutation in 8 (12.1%), and FGFR1 mutation in 4 (6.1%). Spontaneous hemorrhage was observed in 5 patients (7.6%); 4 of them had an FGFR1 mutation and 1 had K-B fusion. Univariate analysis revealed a statistically significant association of an FGFR1 mutation and a diencephalic location with spontaneous hemorrhage. Among 19 diencephalic cases including the optic pathway, hypothalamus, and thalamus, an FGFR1 mutation was significantly associated with spontaneous hemorrhage (p < 0.001). Four FGFR1 mutation cases illustrated the following results: 1) a 2-year-old female with pilomyxoid astrocytoma (PMA) harboring the FGFR1 K656E mutation presented with intraventricular hemorrhage (IVH); 2) a 6-year-old male with PMA harboring FGFR1 K656E and D652G mutations presented with intratumoral hemorrhage (ITH); 3) a 4-year-old female with diffuse astrocytoma harboring FGFR1 K656M and D652G mutations presented with IVH; and 4) a young adult patient with pilocytic astrocytoma with the FGFR1 N546K mutation presented with delayed ITH and IVH after 7 years of observation. CONCLUSIONS: Although the mechanism remains unclear, the FGFR1 mutation is associated with spontaneous hemorrhage in pediatric and young adult LGG. - Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature.
Soichiro Takamiya; Kanako C Hatanaka; Yukitomo Ishi; Toshitaka Seki; Shigeru Yamaguchi
Neuropathology : official journal of the Japanese Society of Neuropathology, 40, 3, 275, 279, 2020年01月27日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), A 17-year-old female complained of lower extremity pain that progressed to low back pain accompanied by paraparesis. Magnetic resonance imaging revealed a mass in the conus medullaris of the spinal cord at the thoracic spine 11-12 level. The patient underwent resection of the mass. The pathological diagnosis was anaplastic astrocytoma based on the densely proliferating astrocytic tumor cells without necrosis or microvascular proliferation. The patient received chemoradiotherapy with oral temozolomide and a total of 54 Gy of local irradiation, followed by 24 courses of temozolomide as maintenance chemotherapy. The patient survived for 8 years without tumor recurrence following the initial treatment. Genetic analysis of the tumor revealed a BRAF V600E mutation that has not yet been reported in spinal cord high-grade gliomas (HGGs). In recent years, the molecular therapy targeting the BRAF V600E mutation has been applied in clinical practice for several cancer types. Although the frequency in spinal cord HGGs is uncertain, it is necessary to investigate BRAF V600E mutation as a potential therapeutic target in the future. - ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
Yukitomo Ishi
Neuro-Oncology, 2020年
研究論文(学術雑誌) - PROTON BEAM RADIOTHERAPY FOR PEDIATRIC AND YOUNG-ADULT PATIENTS WITH INTRACRANIAL GERM CELL TUMOR
Yukitomo Ishi
Neuro-Oncology, 2020年
研究論文(学術雑誌) - 6. PROTON BEAM THERAPY FOR PATIENTS WITH INTRACRANIAL EPENDYMOMA UNDER 3 YEARS OLD: INITIAL CLINICAL OUTCOMES
Yukitomo Ishi
Neuro-Oncology, 2020年
研究論文(学術雑誌) - 化学療法導入直後に急激な嚢胞性増大を示した卵黄嚢腫瘍主体の頭蓋内胚細胞腫瘍の1例
澤谷亮佑; 山口秀; 伊師雪友; 茂木洋晃; 小林浩之; 杉山未奈子; 長祐子; 井口晶裕; 大塚拓也; 今本鉄平; 高桑恵美; 寳金清博
脳神経外科速報, 30, 3, 300, 305, (株)メディカ出版, 2020年, [査読有り]
日本語 - Simplified Dural Reconstruction Procedure Using Biocompatible Polyglycolic Acid Felt with Autologous Abdominal Fat Grafts after a Transpetrosal Approach.
Shigeru Yamaguchi; Shunsuke Terasaka; Michinari Okamoto; Yukitomo Ishi; Hiroaki Motegi; Hiroyuki Kobayashi; Kiyohiro Houkin
World neurosurgery, 132, e710-e715, 2019年12月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Dural reconstruction after transpetrosal approaches is complicated because complete primary closure of presigmoid dura mater is difficult to achieve. To address this problem, we use biocompatible polyglycolic acid (PGA) felt (Durawave) to reconstruct dural defects. To evaluate the use of PGA felt in dural reconstruction, we compared these results with those after conventional duraplasty using autologous fascia grafts. METHODS: We retrospectively surveyed all cases involving a transpetrosal approach reported since 2013. In the conventional procedure, autologous fascia was fixed over the dural defect using stay sutures; any remaining dead space was obliterated by placing abdominal fat grafts. Since April 2017, we have used PGA felt instead of fascia. RESULTS: Of the 37 cases identified, 27 were reconstructed according to the conventional procedure, and the remaining 10 cases were reconstructed using PGA felt. Among the 27 conventional cases, 8 involved cerebrospinal fluid (CSF)-related complications, including 3 cases of rhinorrhea and 5 cases of subcutaneous fluid collection, and 2 cases (7%) required repair surgery. Of the 10 cases involving PGA felt, 1 case (10%) involved subcutaneous fluid collection and required repair surgery, and whereas the remaining 9 cases had no evidence of CSF leakage. In addition, the median dural reconstruction time using PGA felt was 9 minutes, significantly shorter than that when autologous fascia was used (median, 44 minutes). CONCLUSIONS: Using PGA felt for presigmoid dura simplifies dural reconstruction because it obviates the need to suture in a deep field. PGA felt has the potential to prevent CSF-related complications after transpetrosal approaches. - Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
Chongxian Hou; Yukitomo Ishi; Hiroaki Motegi; Michinari Okamoto; Yafei Ou; Jiawei Chen; Shigeru Yamaguchi
Journal of neuro-oncology, 145, 2, 201, 210, 2019年11月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Overexpression of CD44 has been detected in many types of tumor tissues. Moreover, CD44 is recognized as a cancer stem cell marker for many cancers. However, the prognostic value of CD44 for glioma patients has not yet been clarified. The authors tried to explore the impact of CD44 expression on grade II/III glioma patients. METHODS: To assess the RNA expression levels of CD44 in glioma tissues and normal brain tissues, meta-analyses were conducted in the online Oncomine database. The mRNA expression levels of CD44, CD44s, and CD44v2-v10 in 112 grade II/III glioma patients in Hokkaido University Hospital (HUH) were detected by qPCR. The RNA-seq data and clinical data of grade II/III glioma patients were obtained from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. RESULTS: Based on the Oncomine database, CD44 has significantly high expression in glioma tissues as compared with normal tissues. We explored the clinical relevance of CD44 mRNA expression based on the HUH cohorts, the TCGA cohorts, and the CGGA cohorts. In survival analysis, high mRNA expression of CD44 was correlated with poor overall survival and poor progression-free survival in grade II/III glioma patients. Multivariate Cox regression analyses confirmed CD44 as an independent prognostic factor for grade II/III glioma patients. CONCLUSIONS: The present study suggests that overexpression of CD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest that CD44 could serve as a prognostic biomarker in grade II/III glioma patients. - Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas.
Yukitomo Ishi; Shigeru Yamaguchi; Michiharu Yoshida; Hiroaki Motegi; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
Journal of neuroradiology = Journal de neuroradiologie, 48, 4, 266, 270, 2019年06月20日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND AND PURPOSE: Most individuals with optic pathway/hypothalamic pilocytic astrocytoma (OPHPA) harbor either the BRAF V600E mutation or KIAA1549-BRAF fusion (K-B). This study aimed to investigate the imaging characteristics of OPHPA in relation to BRAF alteration status. MATERIALS AND METHODS: Seven cases of OPHPA harboring either the BRAF V600E mutation or K-B fusion were included in the study. Preoperative magnetic resonance imaging (MRI) was assessed for degree of T2 hyperintensity on T2-weighted images (T2WI) and the ratio of nonenhancing T2 or fluid-attenuated inversion recovery (FLAIR) hyperintense area to the contrast enhanced area (CE) on gadolinium-enhanced-T1 weighted images (T2/FLAIR-CE mismatch). The T2 signal intensity was normalized to cerebrospinal fluid (T2/CSF) for both the V600E and K-B group and compared. T2/FLAIR-CE mismatch was assessed by calculating the proportion of the tumor volume of nonenhancing high T2 signal intensity to the whole lesion (nonenhancing and enhancing components). RESULTS: Four and three cases of OPHPA harboring the BRAF V600E mutation and K-B, respectively, were analyzed. The T2/CSF value was higher in the K-B group than in the V600E group. Moreover, the V600E group had a larger T2/FLAIR-CE mismatch than the K-B group. CONCLUSIONS: The BRAF alteration status in individuals with OPHPA was associated with preoperative MRI by focusing on T2 signal intensity and T2/FLAIR-CE mismatch. The BRAF V600E mutation was associated with a lower T2/CSF value and larger T2/FLAIR-CE mismatch, whereas K-B fusion was associated with a higher T2/CSF value and smaller T2/FLAIR-CE mismatch. - Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas.
Chongxian Hou; Shigeru Yamaguchi; Yukitomo Ishi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Kanako C Hatanaka; Kiyohiro Houkin
Journal of neuro-oncology, 143, 2, 197, 206, 2019年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) appears to be a promising treatment for glioma. However, 5-ALA-mediated fluorescence cannot always be detected in grade II/III gliomas. We hypothesized that gene expression patterns in the Protoporphyrin IX (PpIX) synthesis pathway may be associated with intraoperative fluorescence status of grade II/III gliomas, and then attempted to identify the key molecule of 5-ALA-mediated fluorescence. METHODS: Using 50 surgically obtained specimens, which were diagnosed as grade II and III gliomas, we analyzed gene expression within the PpIX synthesis pathway to identify candidate molecules according to intraoperative 5-ALA-mediated fluorescence status. The most likely candidate gene was selected and confirmed by protein expression analysis. To evaluate the biological function of the molecule in PpIX synthesis, functional analysis was performed using specific, small interference (si)RNA in the SW-1783 human grade III glioma cell line. RESULTS: Among the genes involved in the porphyrin synthesis pathway, the mRNA expression of Peptide transporter 2 (PEPT2) in FGS fluorescence-positive gliomas was significantly higher than that in fluorescence-negative gliomas. Protein expression of PEPT2 was also significantly higher in the fluorescence-positive gliomas, which was confirmed by western blot analysis and immunofluorescence analysis. The siRNA-mediated downregulation of the mRNA and protein expression of PEPT2 led to decreased PpIX fluorescence intensity, as confirmed by fluorescence spectrum analysis. CONCLUSIONS: The results suggest PEPT2 is an important candidate molecule in 5-ALA-mediated FGS in grade II/III gliomas. As the overexpression of PEPT2 was associated with higher PpIX fluorescence intensity, PEPT2 may improve fluorescence-guided resection in grade II/III gliomas. - Retrosigmoid Intradural Suprameatal Approach for Petroclival Meningioma.
Yukitomo Ishi; Shunsuke Terasaka; Hiroaki Motegi
Journal of neurological surgery. Part B, Skull base, 80, Suppl 3, S296-S297, 2019年06月, [査読有り], [国際誌]
英語, Background Anterior transpetrosal approach and the combined transpetrosal approach are the major surgical approaches for petroclival meningiomas. However, anterior petrosectomy is not preferable in cases with postoperative venous drainage disorder of the sylvian vein due to anatomical variations. Here we present a case of the successful removal of petroclival meningioma by the retrosigmoid intradural suprameatal approach (RISA). Case Presentation The patient was a 59-year-old woman with incidentally detected right petroclival meningioma. Although she had no neurological deficit, the tumor manifested with gradual growth on annual magnetic resonance imaging (MRI) during an 8-year follow-up. Three-dimensional computed tomography venography (3D-CTV) revealed sphenobasal type of the sylvian vein throughout the lateral side of the foramen ovale. Because the suprameatal tubercle was an obstacle to observe the Meckel's cave, RISA was selected for complete tumor excision. RISA could provide an excellent operative field around the Meckel's cave to confirm the remnant tumor. Postoperative MRI showed no evidence of the tumor, and the patient was discharged without any neurological deficit. Conclusion RISA can provide a favorable operative field for petroclival meningioma, particularly for cases with high risk of postoperative complications related to the sylvian vein. The link to the video can be found at: https://youtu.be/cfci_zk0StU . - The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma.
Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Michinari Okamoto; Hiroyuki Kobayashi; Kenji Hirata; Yoshitaka Oda; Shinya Tanaka; Shunsuke Terasaka; Kiyohiro Houkin
Journal of neurosurgical sciences, 64, 6, 502, 508, 2018年07月09日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Although newly diagnosed high-grade glioma patients in Japan can receive bevacizumab (BEV) as first-line chemotherapy, randomized clinical trials have not shown a survival benefit for BEV for these patients. In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ). METHODS: We conducted a retrospective survey of the overall survival (OS) of patients with GBM/AAs who were treated in our institution between 2006 and 2016. Patients whose tumors were continuously growing regardless of radiotherapy were categorized as the "progressive" group; remaining patients were categorized as the "non-progressive" group. Since 2013, patients in the "progressive" group received add-on BEV therapy with the Stupp regimen during or just after radiotherapy. RESULTS: Of 151 GBM/AA patients, 34 (22.5%) were categorized in the "progressive" group. Median OSs of the "progressive" and "non-progressive" groups were 13.2 months and 25.3 months, respectively (P < 0.001). Twelve patients in the "progressive" group received add-on BEV therapy, and their median OS was 20.2 months; whereas for the remaining 22 patients in the "progressive" group who were treated before the BEV era, their median OS was 10.5 months. In the "progressive" group, add-on BEV significantly extended OS (P = 0.018) and was the lone clinical factor of better prognosis. CONCLUSIONS: We found that, for patients with GBM/AAs whose tumors were continuously growing during radiotherapy, add-on BEV treatment resulted in survival benefits. - Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens
Yukitomo Ishi; Kanako C. Hatanaka; Shigeru Yamaguchi; Hiromi Fujita; Hiroaki Motegi; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
BRAIN TUMOR PATHOLOGY, 34, 4, 165, 171, 2017年10月, [査読有り]
英語, 研究論文(学術雑誌) - Change in F-18-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment
Shigeru Yamaguchi; Kenji Hirata; Takuya Toyonaga; Kentaro Kobayashi; Yukitomo Ishi; Hiroaki Motegi; Hiroyuki Kobayashi; Tohru Shiga; Nagara Tamaki; Shunsuke Terasaka; Kiyohiro Houkin
PLOS ONE, 11, 12, e0167917, 2016年12月, [査読有り]
英語, 研究論文(学術雑誌) - Reliability of the Size Evaluation Method for Meningiomas: Maximum Diameter, ABC/2 Formula, and Planimetry Method
Yukitomo Ishi; Shunsuke Terasaka; Shigeru Yamaguchi; Michiharu Yoshida; Shogo Endo; Hiroyuki Kobayashi; Kiyohiro Houkin
WORLD NEUROSURGERY, 94, 80, 88, 2016年10月, [査読有り]
英語, 研究論文(学術雑誌) - Primary pineal rhabdomyosarcoma successfully treated by high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation: case report
Yukitomo Ishi; Shigeru Yamaguchi; Akihiro Iguchi; Yuko Cho; Junjiro Ohshima; Kanako C. Hatanaka; Emi Takakuwa; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin
JOURNAL OF NEUROSURGERY-PEDIATRICS, 18, 1, 41, 45, 2016年07月, [査読有り]
英語, 研究論文(学術雑誌) - Application of endoscopic ultrasonography to intraventricular lesions
Hiroaki Motegi; Hiroyuki Kobayashi; Shunsuke Terasaka; Shigeru Yamaguchi; Yukitomo Ishi; Yasuhiro Ito; Kiyohiro Houkin
ACTA NEUROCHIRURGICA, 158, 1, 87, 92, 2016年01月, [査読有り]
英語, 研究論文(学術雑誌) - 全身血管病に起因する頚部内頚動脈解離性動脈瘤に対してstent-assisted coil embolizationが有効であった1例
高宮宗一朗; 長内俊也; 牛越聡; 栗栖宏多; 下田祐介; 伊藤康裕; 伊師雪友; 穂刈正昭; 中山若樹; 数又研; 鐙谷武雄; 七戸秀夫; 寳金清博
Neurological Surgery, 44, 1, 39, 45, 2016年, [査読有り], [国内誌]
日本語, Systemic vascular diseases such as fibromuscular dysplasia, Ehlers-Danlos syndrome, Marfan syndrome, and Behçet's disease are known to cause spontaneous dissecting aneurysms of the cervical internal carotid artery. These diseases are generally associated with vascular fragility; therefore, invasive treatments are avoided in many cases of dissecting aneurysms, and a conservative approach is used for the primary disease. Surgical or intravascular treatment may be chosen when aneurysms are progressive or are associated with a high risk of hemorrhage; however, there is no consensus on which treatment is better. We report a case of a dissecting aneurysm of the cervical internal carotid artery in a patient with suspected Behçet's disease, which was treated using stent-assisted coil embolization. A man in his 40's, with suspected Behçet's disease, presented with an enlarged dissecting aneurysm of the right cervical internal carotid artery. The lesion was present for approximately 10 years. We performed stent-assisted coil embolization for the lesion. Post-surgery, no aneurysms were detected with carotid artery echography. Our case report suggests that stent-assisted coil embolization is a promising treatment for dissecting aneurysms of the cervical internal carotid artery. In addition, the procedure demonstrates the utility of carotid artery echograms for examining recanalization after stent-assisted coil embolization. - Endoscopic transsphenoidal surgery using pedicle vascularized nasoseptal flap for cholesterol granuloma in petrous apex: A technical note
Yukitomo Ishi; Hiroyuki Kobayashi; Hiroaki Motegi; Shogo Endo; Shigeru Yamaguchi; Shunsuke Terasaka; Kiyohiro Houkin
NEUROLOGIA I NEUROCHIRURGIA POLSKA, 50, 6, 504, 510, 2016年, [査読有り]
英語, 研究論文(学術雑誌) - Idiopathic fourth ventricle outlet obstruction successfully treated by endoscopic third ventriculostomy: a case report
Yukitomo Ishi; Katsuyuki Asaoka; Hiroyuki Kobayashi; Hiroaki Motegi; Taku Sugiyama; Yuka Yokoyama; Sumire Echizenya; Koji Itamoto
SPRINGERPLUS, 4, 565, 2015年09月, [査読有り]
英語, 研究論文(学術雑誌) - Case report: Trigeminal neuralgia caused by a minute meningioma with hyperostosed suprameatal tubercle
Yukitomo Ishi; Katsuyuki Asaoka; Taku Sugiyama; Yuka Yokoyama; Kazuyoshi Yamazaki; Sumire Echizenya; Koji Itamoto; Kohei Echizenya
Case Reports in Neurology, 7, 2, 167, 172, S. Karger AG, 2015年05月13日, [査読有り]
英語, 研究論文(学術雑誌) - Utility of 4D-MRA to Measure Blood Flow Velocity in Cerebral Major Arteries
Yukitomo Ishi
Stroke, 46, 2015年02月, [査読有り]
研究論文(学術雑誌) - 受傷後早期に吸収された乳児急性硬膜外血腫の1例
伊師雪友; 浅岡克行; 杉山拓; 越前谷すみれ; 横山由佳; 板本孝治
Neurological Surgery, 43, 4, 352, 356, Igaku-Shoin Ltd, 2015年, [査読有り]
日本語 - 悪性神経膠腫におけるギリアデル留置後の有害事象とその要因の検討
吉田道春; 山口秀; 伊師雪友; 遠藤将吾; 茂木洋晃; 小林浩之; 浅岡克行; 鴨嶋雄大; 寺坂俊介; 寳金清博
Neurological Surgery, 43, 7, 603, 610, Igaku-Shoin Ltd, 2015年, [査読有り]
日本語 - Successful removal of a metastatic gastrointestinal stromal tumor in the craniovertebral junction using an occipital artery to posterior inferior cerebellar artery bypass
Yukitomo Ishi; Naoki Nakayama; Hiroyuki Kobayashi; Shigeru Yamaguchi; Shunsuke Terasaka; Kiyohiro Houkin
Case Reports in Neurology, 6, 2, 139, 143, S. Karger AG, 2014年04月16日, [査読有り]
英語, 研究論文(学術雑誌) - 脊髄空洞症を合併した硬膜内くも膜嚢胞の1例
伊師雪友; 青山剛; 栗栖宏多; 飛騨一利; 寳金清博
Neurological Surgery, 42, 5, 467, 472, Igaku-Shoin Ltd, 2014年, [査読有り]
日本語 - 補助人工心臓装着患者の脳塞栓症に対して急性期血管内治療が奏功した1例
小林聡; 宮本倫行; 宮本倫行; 品田伸一郎; 伊師雪友; 下田祐介; 山崎和義; 牛越聡; 牛越聡; 大岡智学; 松居喜郎; 寳金清博
Neurological Surgery, 42, 11, 1057, 1062, Igaku-Shoin Ltd, 2014年, [査読有り]
日本語 - 脳卒中で発症したreversible cerebral vasoconstriction syndromeの3例
伊師雪友; 杉山拓; 越前谷すみれ; 横山由佳; 浅岡克行; 板本孝治
Neurological Surgery, 42, 2, 129, 36, 2014年, [国内誌]
日本語, Reversible cerebral vasoconstriction syndrome(RCVS)is characterized by severe headache and diffuse segmental constriction of cerebral arteries that resolves spontaneously within a few months. Although manifestations of stroke are not included in diagnostic criteria of RCVS, it is known that some cases may be associated with stroke, including intracerebral hemorrhage, subarachnoid hemorrhage, or cerebral infarction. We present three cases of RCVS associated with various types of stroke, and then review the literature. Case 1:A 49-year-old woman presented with a headache followed by left hemiparesis and dysarthria. One month before the onset, she was transfused for severe anemia caused by uterus myoma. CT images revealed intracerebral hemorrhages in the right putamen and right occipital lobe. Angiography revealed multiple segmental constrictions of the cerebral arteries. One month after the onset, these vasoconstrictions improved spontaneously. Case 2:A postpartum 38-year-old woman who had a history of migraine presented with thunderclap headache. Imaging revealed a focal subarachnoid hemorrhage in the right postcentral sulcus and segmental vasoconstriction of the right middle cerebral artery. One week after the onset, this vasoconstriction improved spontaneously. Case 3:A 32-year-old woman who had a history of migraine presented with headache followed by left homonymous hemianopsia. Imaging revealed a cerebral infarction of the right occipital lobe and multiple constrictions of the right posterior cerebral artery. These vasoconstrictions gradually improved spontaneously. - Surgical treatment of pyogenic spondylitis using posterior fusion
Yukitomo Ishi; Takeshi Aoyama; Kazutoshi Hida; Tomohiro Yamauchi; Shunsuke Yano; Toru Sasamori; Jun-Ichi Murata
Neurological Surgery, 41, 11, 1017, 1021, 2013年11月, [査読有り]
日本語, 研究論文(学術雑誌) - 髄上皮腫類似の病理像を呈したテント上primitive neuroectodermal tumorの1例
伊師雪友; 鈴木望; 高杉和雄; 津田宏重; 立野正敏; 立野正敏; 田中伸哉
Neurological Surgery, 40, 2, 159, 165, 2012年, [査読有り]
日本語 - Suprahepatic spaceへの脳室腹腔シャント腹腔端の再建
伊師雪友; 伊東雅基; 寺坂俊介; 茂木洋晃; 新保大輔; 金子貞洋; 寳金清博
Neurological Surgery, 39, 11, 1061, 1066, 2011年, [査読有り]
日本語 - 広範なくも膜下出血を呈し診断に苦慮した下垂体卒中の一例
伊師雪友; 加藤功; 竹田誠; 松崎隆幸
脳神経外科速報, 21, 8, 918, 923, (株)メディカ出版, 2011年, [査読有り]
日本語, 83歳女。高血圧で内服加療中、突然のめまいと嘔吐で救急搬送された。頭部CTで広範なくも膜下出血を認め、CT angiography、脳血管造影検査で出血源は明らかでなく、分布が中脳前方から鞍上部槽に限局していることから当初はperimesencephalic SAHと考え保存的治療を開始した。後日、家族からの情報で過去に鞍上部腫瘍を指摘されていたことが明らかとなり、3年前のMRI画像の検討で鞍内から鞍上部にかけて下垂体腺腫と考えられる病変を認めた。第13病日にMRIを施行したが、残存するくも膜下出血のため腫瘤性病変は指摘できず、第62病日に再度MRIを施行したところ、鞍内から鞍上部にかけて不均一に造影される部分を認め、下垂体腺腫からの出血により腫瘍形態が変化したと考えられた。下垂体ホルモン測定でホルモン産生腫瘍を示唆する所見は認めず、非機能性下垂体腺腫の存在下での下垂体卒中からの出血がくも膜下出血の原因と判断した。経過中に脳血管攣縮による右前頭葉の脳梗塞、水頭症を合併しADLの低下を来たしたが、脳室腹腔シャント術後は徐々に改善し、第90病日にリハビリ目的で転院となった。 - フィブリン製剤に対するアレルギー反応により術後に脳梗塞を来した未破裂脳動脈瘤の一例
伊師雪友; 竹田誠; 加藤功
函館中央病院医誌, 13, 1, 4, 函館中央病院, 2011年, [査読有り]
日本語, 45歳女。網膜中心動脈閉塞症に対する精査目的に施行したMRIで未破裂脳動脈瘤を指摘され、クリッピング術を目的に入院となった。開頭クリッピング術を施行し、閉頭時はゼラチン製剤(Gelform)とフィブリン製剤(BOLHEAL)の併用によるくも膜形成を行い、硬膜形成後に再度BOLHEALを噴霧した。術後7日目の3D-CTAで、左M2から末梢にごく軽度の描出不良を認めた。顔面を含む右片麻痺と失語が出現した。MRIでは左前頭葉、側頭葉、頭頂葉にかけて新鮮な脳梗塞を認め、何らかの原因による脳血管攣縮と考え、塩酸ファスジルの動脈内投与を施行したところ、脳血管攣縮の改善を認めた。右片麻痺は改善し、軽度の失語が残存した。脳血管攣縮の原因は不明のままであったが、発症から4年後にフィブリン製剤に対する薬剤リンパ球刺激試験が陽性で、アレルギー反応による脳血管攣縮が脳梗塞の原因であったことが示唆された。
- 主要な遺伝子異常を認めない小児神経膠腫の頻度と臨床像
山口 秀; 伊師 雪友; 山本 大慈; 寺下 友佳代; 平林 真介; 種井 善一; 田中 伸哉; 長 祐子; 真部 淳; 藤村 幹, Brain Tumor Pathology, 43, Suppl., 139, 139, 2026年06月
日本脳腫瘍病理学会, 日本語 - 脂肪細胞を伴う中枢性神経細胞腫のDNAメチル化解析
桑原 傑; 伊師 雪友; 小田 義崇; 種井 善一; 杉野 弘和; 茂木 洋晃; 津田 真寿美; 山口 秀; 藤村 幹; 田中 伸哉, Brain Tumor Pathology, 43, Suppl., 145, 145, 2026年06月
日本脳腫瘍病理学会, 日本語 - 骨変形を伴い長期経過が疑われるDiffuse pediatric-type high-gradeの一例
山田 芳郎; 山口 秀; 伊師 雪友; 種井 善一; 田中 伸哉; 寺下 友佳代; 西岡 健太郎; 原田 太以佑; 真部 淳; 藤村 幹, Brain Tumor Pathology, 43, Suppl., 166, 166, 2026年06月
日本脳腫瘍病理学会, 日本語 - HMGA2遺伝子再構成を有する涙腺多形腺腫由来癌肉腫の一例(A case of carcinosarcoma ex pleomorphic adenoma of the lacrimal gland with HMGA2 gene rearrangement)
高橋 利明; 種井 善一; 伊師 雪友; 山口 秀; 水門 由佳; 清水 亜衣; 岡田 宏美; 大塚 紀幸; 外丸 詩野; 田中 伸哉, 日本病理学会会誌, 115, 1, 388, 388, 2026年03月
(一社)日本病理学会, 英語 - Primary diffuse meningeal melanomatosisの一例(A case of primary diffuse meningeal melanomatosis)
宮石 陸; 岡田 宏美; 大木 聡悟; 伊師 雪友; 山口 秀; 種井 善一; 清水 亜衣; 大塚 紀幸; 外丸 詩野; 田中 伸哉, 日本病理学会会誌, 115, 1, 483, 483, 2026年03月
(一社)日本病理学会, 英語 - HMGA2遺伝子再構成を有する涙腺多形腺腫由来癌肉腫の一例(A case of carcinosarcoma ex pleomorphic adenoma of the lacrimal gland with HMGA2 gene rearrangement)
高橋 利明; 種井 善一; 伊師 雪友; 山口 秀; 水門 由佳; 清水 亜衣; 岡田 宏美; 大塚 紀幸; 外丸 詩野; 田中 伸哉, 日本病理学会会誌, 115, 1, 388, 388, 2026年03月
(一社)日本病理学会, 英語 - Primary diffuse meningeal melanomatosisの一例(A case of primary diffuse meningeal melanomatosis)
宮石 陸; 岡田 宏美; 大木 聡悟; 伊師 雪友; 山口 秀; 種井 善一; 清水 亜衣; 大塚 紀幸; 外丸 詩野; 田中 伸哉, 日本病理学会会誌, 115, 1, 483, 483, 2026年03月
(一社)日本病理学会, 英語 - 初発から10年以上経過して再手術が行われた毛様細胞性星細胞腫の病理学的検討
伊師雪友; 山口秀; 宮石陸; 岡田宏美; 小田義崇; 杉野弘和; 田中伸哉; 田中伸哉; 大木聡悟; 小柳泉; 藤村幹, Brain Tumor Pathology. Supplement, 42, 2025年 - 成人テント上星細胞腫Grade4の画像所見・臨床所見・治療成績
山口秀; 伊師雪友; 大木聡悟; 藤村幹, 日本脳神経CI学会総会プログラム・抄録集, 48th, 2025年 - 成長ホルモン産生下垂体腫瘍におけるβ-カテニンの細胞内局在と病理型・臨床経過との関連
桑原咲; 亀田啓; 野本博司; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也, 日本内分泌学会雑誌, 101, 1, 2025年 - 小児脳神経外科 髄芽腫の治療進歩と展望
山口秀; 伊師雪友; 藤村幹, 脳神経外科ジャーナル, 34, 4, 2025年 - 成長ホルモン産生下垂体腫瘍におけるWnt/β-カテニン経路と細胞増殖ならびにsparsely granulated typeとの関連
桑原咲; 亀田啓; 野本博司; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也, 日本間脳下垂体腫瘍学会プログラム・抄録集, 35th, 2025年 - Microadenomaで発見されたTSH産生下垂体腺腫/PitNETの検討
伊師雪友; 亀田啓; 萬田悟; 大木聡悟; 山口秀; 原田太以佑; 清水幸衣; 清水亜衣; 加藤憲士郎; 藤村幹, 日本間脳下垂体腫瘍学会プログラム・抄録集, 35th, 2025年 - 内視鏡下経鼻的経蝶形骨洞手術における中床突起切除の意義
水嶋慎; 茂木洋晃; 大木聡悟; 岡本迪成; 伊師雪友; 山口秀; 藤村幹, 日本頭蓋底外科学会プログラム・抄録集, 37th, 2025年 - 耳性脳膿瘍に対する耳鼻咽喉科との一期的合同手術
伊師雪友; 森田真也; 福田篤; 大木聡悟; 山口秀; 藤村幹, 日本頭蓋底外科学会プログラム・抄録集, 37th, 2025年 - 包括的がんゲノムプロファイリング検査における小児がんの二次的所見の検討
齋藤祐介; 寺下友佳代; 平林真介; 安部樹太朗; 大浦果寿美; 長祐子; 柴田有花; 向中野実央; 藤田穂波; 有賀伸; 天野虎次; 萩尾加奈子; 山口秀; 伊師雪友; 木下一郎; 山田崇弘; 真部淳, 日本遺伝カウンセリング学会誌, 46, 2, 2025年 - FREQUENT MULTIFOCAL INTRATUMORAL HEMORRHAGE IN MULTIPLE BRAIN METASTASES FROM HEPATOCELLULAR CARCINOMA
Yukitomo Ishi; Kentaro Nishioka; Shigeru Yamaguchi; Michinari Okamoto; Hiroaki Motegi; Sogo Oki; Takashi Mori; Hidefumi Aoyama; Miki Fujimura, NEURO-ONCOLOGY, 26, 2024年11月11日
英語, 研究発表ペーパー・要旨(国際会議) - 再発時にチラブルチニブが奏功した脊髄原発悪性リンパ腫の一例
伊師雪友; 茂木洋晃; 高宮宗一朗; 清水亜衣; 奥山友浩; 水嶋慎; 大木聡悟; 岩崎素之; 山口秀; 藤村幹, 日本脊髄外科学会プログラム・抄録集, 39th, 2024年 - 視路視床下部神経膠腫再発に対する化学療法を中心とした治療戦略
山口 秀; 伊師 雪友; 茂木 洋晃; 大木 聡悟; 寺下 友佳代; 長谷河 昌孝; 長 祐子; 平林 真介; 真部 淳; 藤村 幹, 小児の脳神経, 49, 3, 81, 87, 2024年
視路視床下部低悪性度神経膠腫(OPHG)に対して,再発時の治療に関して化学療法を中心とした治療戦略としている.本治療戦略で治療を行ったOPHG症例の再発時化学療法の治療効果を中心に検討した.2007年以降の初発18例のうち12例で再発を認めた(中央値29か月).再発時の治療として化学療法が8例で選択され,カルボプラチンを中心とした化学療法レジメンが最も有用であり,6例中4例で治療効果が得られた.本治療戦略において視機能を含めた神経機能予後は良好であったが,腎毒性を中心とした合併症が課題である., 一般社団法人 日本小児神経外科学会, 日本語 - 当院におけるキャンサーボードを中心とした小児脳腫瘍診療体制の構築
山口 秀; 伊師 雪友; 茂木 洋晃; 寺下 友佳代; 平林 真介; 橋本 孝之; 真部 淳; 藤村 幹, 日本小児血液・がん学会雑誌, 61, 2, 154, 158, 2024年
小児脳腫瘍は希少疾患である.医師個人が経験できる症例は限られているため,個人の経験と直感に基づいた治療方針の決定は患者に有益とはならず,可能な限りの治療の均てん化は必須であろう.そのためには集約化のみでなく,一例毎の情報と経験の共有が大変重要となる.
当院では小児脳腫瘍の診断治療にあたり,脳神経外科・小児科・放射線治療科を主体とする小児脳腫瘍キャンサーボードを中心としたシームレスな診療体制を構築している.週1回定期的に開催し,治療中の患者の情報共有,新患紹介と治療方針の検討,転科調整等を行うことで,経験症例の共有・治療効果の客観性の確保・治療タイムラグの減少が可能となっている.全症例を本ボードで検討し,診療科に拘らない適切かつ迅速な初期対応・治療を志している.
2013年に当院が小児がん拠点病院に選定されてから,161例の20歳未満初発小児脳腫瘍患者の治療を行った.初発から対応したのは150例であり,内訳は低悪性度神経膠腫28例,悪性神経膠腫22例,上衣腫9例,胚細胞腫瘍27例,髄芽腫等の胎児性腫瘍21例等であった.初発時診断では,本ボード上での協議で9例(胚細胞腫瘍6例,低悪性度神経膠腫3例)が組織診断なしでの診断確定を合意し,後療法を施行した.治療後残存病変に対して追加摘出術に関しても,必要性や時期は本ボード上の協議にて決定された.年齢に応じた治療方針や晩期障害を見据えた化学療法・放射線治療の選択,他施設からの相談症例に関しても本ボードでの討議事項である.治療に関わる複数科医師での合意・共通疾患認識が重要であり,本ボードがその中心の役割を果たしている., 日本小児血液・がん学会, 日本語 - 当院におけるキャンサーボードを中心とした小児脳腫瘍診療体制の構築
山口秀; 伊師雪友; 茂木洋晃; 寺下友佳代; 平林真介; 橋本孝之; 真部淳; 藤村幹, 日本小児血液・がん学会雑誌(Web), 61, 2, 2024年 - 膠芽腫治療における放射線治療後残存・増大病変に対する追加切除術
山口秀; 伊師雪友; 大木聡悟; 茂木洋晃; 藤村幹, 日本脳腫瘍の外科学会プログラム・抄録集, 29th, 2024年 - 視路視床下部神経膠腫再発に対する化学療法を中心とした治療戦略
山口秀; 伊師雪友; 茂木洋晃; 大木聡悟; 寺下友佳代; 長谷河昌孝; 長祐子; 平林真介; 真部淳; 藤村幹, 小児の脳神経(Web), 49, 3, 2024年 - 経鼻内視鏡下に生検術を行った成人発症の視床下部組織球症の一例
伊師雪友; 高桑恵美; 岡田宏美; 松川敏大; 小島圭祐; 遠藤知之; 大木聡悟; 山口秀; 藤村幹, 日本神経内視鏡学会プログラム・抄録集, 31st, 2024年 - Tumefactive demyelinating lesionと鑑別を要した膠芽腫の1例
武石侑杜; 上床尚; 穴田麻眞子; 岩見昂亮; 芳野正修; 野村太一; 藤井信太朗; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 白井東磨; 伊師雪友; 山口秀; 若林健人; 外丸詩野; 深澤俊行; 矢部一郎, 臨床神経学(Web), 64, 11, 2024年 - GHRP-2併用海綿静脈洞サンプリングを行った下垂体腫瘍の一例
横関恵; 亀田啓; 宮愛香; 伊師雪友; 茂木洋晃; 茂木洋晃; 長内俊也; 中村昭伸; 渥美達也, 臨床内分泌代謝Update抄録集(Web), 34th, 2024年 - IDH変異神経膠腫に対するLast-line Bevacizumabの治療成績
山口秀; 伊師雪友; 大木聡悟; 澤谷亮佑; 茂木洋晃; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 42nd, 2024年 - 神経膠腫を併発しMLH1とATM遺伝子の生殖細胞系列変異を同時に認めたLynch症候群の一例
伊師雪友; 茂木洋晃; 茂木洋晃; 山口秀; 大木聡悟; 萩尾加奈子; 木下一郎; 種井善一; 田中伸哉; 田中伸哉; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 42nd, 2024年 - 可逆性後頭葉白質脳症を合併したクッシング病の1例
住田無限; 亀田啓; 大江悠希; 大江悠希; 古澤翔; 萬田悟; 大西錦之介; 大藤悠理; 伊藤悠菜; 宮愛香; 伊師雪友; 茂木洋晃; 中村昭伸; 渥美達也, 日本内分泌学会北海道支部学術集会プログラム・抄録(Web), 24th, 2024年 - 経鼻的下垂体腫瘍摘出術後に多尿を呈し,中枢性尿崩症と腎性尿崩症の合併と考えられた1例
住田無限; 亀田啓; 大西錦之介; 宮愛香; 伊師雪友; 茂木洋晃; 中村昭伸; 渥美達也, 日本内分泌学会北海道支部学術集会プログラム・抄録(Web), 24th, 2024年 - 脳腫瘍治療 2 学びなおしの脳腫瘍治療とケア〈1〉脳腫瘍の治療-化学療法,放射線治療,外科治療 神経膠腫に対する化学療法
伊師雪友, Brain Nursing, 40, 1, 2024年 - 脳腫瘍治療 2 学びなおしの脳腫瘍治療とケア〈1〉脳腫瘍の治療-化学療法,放射線治療,外科治療 神経膠腫に対する腫瘍摘出術
伊師雪友, Brain Nursing, 40, 1, 2024年 - 脳腫瘍治療 1 ここが変わった!神経膠腫の治療新時代 交流電場腫瘍治療
伊師雪友, Brain Nursing, 40, 1, 2024年 - 脳腫瘍治療 1 ここが変わった!神経膠腫の治療新時代 遺伝子診断の役割
伊師雪友, Brain Nursing, 40, 1, 2024年 - 内視鏡下拡大経蝶形骨洞手術による頭蓋咽頭腫の治療成績
茂木洋晃; 山口秀; 大木聡悟; 澤谷亮佑; 岡本迪成; 越前谷すみれ; 伊師雪友; 藤村幹, 日本間脳下垂体腫瘍学会プログラム・抄録集, 34th, 2024年 - 成長ホルモン産生下垂体腫瘍においてWnt/β-カテニン経路は細胞増殖に関連する
桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也, 日本内分泌学会雑誌, 100, 1, 2024年 - AFP上昇を伴う未熟奇形腫の治療
山口秀; 伊師雪友; 大木聡悟; 茂木洋晃; 長谷河昌孝; 寺下友佳代; 平林真介; 西岡健太郎; 橋本孝之; 真部淳; 藤村幹, 小児の脳神経(Web), 49, 2, 2024年 - 頭蓋咽頭腫の治療戦略と課題:VEPを用いた視機能温存の試み
茂木洋晃; 山口秀; 大木聡悟; 澤谷亮祐; 岡本迪成; 越前谷すみれ; 伊師雪友; 藤村幹, 小児の脳神経(Web), 49, 2, 2024年 - GH産生下垂体腺腫におけるβ-カテニンの細胞内局在と腫瘍径および術後寛解率
桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也, 日本間脳下垂体腫瘍学会プログラム・抄録集, 33rd, 2023年 - びまん性内在性橋膠腫に対するインシリコスクリーニングを用いた治療薬の同定
伊師雪友; 伊師雪友; 伊師雪友; ZHAO Guisheng; NEWBURY Patrick; CHEKALIN Eugene; ZENG Billy; GLICKSBERG Benjamin S.; WEN Anita; 佐々木貴浩; NAZARIAN Javad; PACOLD Michael E.; BRAT Daniel J.; NICOLAIDES Theodore; CHEN Bin; 山口秀; 橋詰倫太郎; 藤村幹, 日本分子脳神経外科学会プログラム・抄録集, 23rd, 2023年 - 髄膜腫におけるCD44の発現についての検討
澤谷亮佑; 山口秀; 伊師雪友; 岡本迪成; 越前谷すみれ; 茂木洋晃; 藤間憲幸; 藤村幹, 日本分子脳神経外科学会プログラム・抄録集, 23rd, 2023年 - 言語野近傍神経膠腫に対する覚醒下手術を前提とした二段階手術
山口秀; 茂木洋晃; 伊師雪友; 澤谷亮佑; 岡本迪成; 越前谷すみれ; 藤村幹, 日本Awake Surgery学会プログラム・抄録集, 21st, 2023年 - RAD52の阻害は小児脳幹部神経膠腫の放射線治療感受性を亢進させる
伊師雪友; 伊師雪友; 内田栄太; 内田栄太; 内田栄太; 渡邊潤; 渡邊潤; 渡邊潤; ワン ルー; アブダラーバレンシア ヒアム; ガッド サマンサ; 山口秀; 藤村幹; 橋詰倫太郎; 橋詰倫太郎; 橋詰倫太郎, 日本脳腫瘍学会学術集会プログラム・抄録集, 41st, 2023年 - 小脳膠芽腫に対する治療成績
大木聡悟; 山口秀; 茂木洋晃; 伊師雪友; 岡本迪成; 澤谷亮佑; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 41st, 2023年 - 前頭蓋底手術における骨弁感染を避けるための有茎前頭開頭の工夫
茂木洋晃; 山口秀; 伊師雪友; 越前谷すみれ; 岡本迪成; 澤谷亮佑; 大木聡悟; 藤村幹, 日本脳腫瘍の外科学会プログラム・抄録集, 28th, 2023年 - 肝細胞癌の多発脳転移における腫瘍内出血の臨床像
伊師雪友, 日本脳腫瘍の外科学会プログラム・抄録集, 28th, 2023年 - 成長ホルモン産生下垂体腫瘍におけるWnt/β-カテニン経路の細胞増殖への影響
桑原咲; 亀田啓; 野本博司; 曹圭龍; 中村昭伸; 伊師雪友; 茂木洋晃; 藤村幹; 渥美達也, 日本神経内分泌学会学術集会プログラム・抄録集, 49th, 2023年 - 膠芽腫治療における化学走性(ケモタキシス)の応用
澤谷亮佑; 茂木洋晃; 岡本迪成; 越前谷すみれ; 伊師雪友; 山口秀; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 41st, 2023年 - 当院の原発性脳腫瘍患者におけるがん遺伝子パネル検査の実情
山口秀; 茂木洋晃; 澤谷亮佑; 伊師雪友; 寺下友佳代; 平林真介; 杉山未奈子; 齋藤祐介; 木下一郎; 真部淳; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 41st, 2023年 - IDH変異を有する脳幹/脊髄神経膠腫の4例
澤谷亮佑; 伊師雪友; 山口秀; 岡本迪成; 茂木洋晃; 高宮宗一朗; 関俊隆; 大塚拓也; 若林健人; 松野吉宏; 種井善一; 田中伸哉; 藤村幹, 日本脳腫瘍学会学術集会プログラム・抄録集, 39th, 2021年 - PCNSLにおける外科手技の影響:手術後の化学療法までの期間とMTX反応性についての検討
岡本迪成; 山口秀; 伊師雪友; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 38th, 2020年 - 脊髄神経膠腫におけるH3K27M変異, H3K27me3, EZH2発現と予後
伊師雪友; 高宮宗一郎; 関俊隆; 山崎和義; 飛騨一利; 畑中佳奈子; 石田雄介; 小田義崇; 田中伸哉; 田中伸哉; 山口秀, 脊髄外科, 34, 3, 2020年 - 脊髄炎との鑑別に苦慮し,脊髄生検により診断に至ったびまん性正中グリオーマの1例
佐藤翔紀; 伊藤雅基; 井須豊彦; 山崎和義; 伊師雪友; 高宮宗一朗; 舘澤亮大; 澤谷亮佑; 関俊隆; 津坂和文, 臨床神経学(Web), 60, 1, 2020年 - 経鼻内視鏡手術を下支えする鞍底再建技術の変遷とその成果
小林浩之; 寺坂俊介; 茂木洋晃; 山口秀; 伊師雪友; 浅岡克行; 宝金清博; 宝金清博, 日本間脳下垂体腫瘍学会プログラム・抄録集, 30th, 2020年 - 膠芽腫の治療成績:MEPを中心とした術中モニタリングによる術後performance status温存の重要性
山口秀; 茂木洋晃; 伊師雪友; 岡本迪成; 澤谷亮佑; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 25th, 2020年 - 画像診断と病理 形成異常小脳神経節膠腫(Lhermitte-Duclos病)
星野豊; 亀田浩之; 原田太以佑; 工藤與亮; 伊師雪友; 三橋智子; 杉野弘和, 画像診断, 40, 13, 2020年 - ACTH産生下垂体腺腫におけるUSP8変異
伊師雪友; 山口秀; 茂木洋晃; 岡本迪成; 亀田啓, Brain Tumor Pathology (Web), 37, Supplement, 2020年 - BRAF V600E変異を伴う脊髄悪性神経膠腫の一例
高宮宗一朗; 伊師雪友; 関俊隆; 山崎和義; 山口秀; 畑中佳奈子, Brain Tumor Pathology (Web), 37, Supplement, 2020年 - 嗅神経芽細胞腫に対する内視鏡頭蓋底外科
茂木洋晃; 山口秀; 伊師雪友; 岡本迪成; 澤谷亮介; 中薗彬; 鈴木正宣; 中丸裕爾; 本間明宏, 日本神経内視鏡学会プログラム・抄録集, 27th, 2020年 - FGFR1点変異を有する小児・若年成人低悪性度神経膠腫の臨床像
伊師 雪友; 山口 秀; 茂木 洋晃; 小林 浩之; 寺坂 俊介; 寳金 清博, Brain Tumor Pathology, 36, Suppl., 093, 093, 2019年05月
日本脳腫瘍病理学会, 日本語 - 頭蓋内胚細胞腫瘍における放射線化学療法後のsalvage surgeryに関する病理所見からの検討
山口 秀; 茂木 洋晃; 伊師 雪友; 岡本 迪成; 井口 晶裕; 長 祐子; 杉山 未奈子; 橋本 孝之; 岡田 宏美; 寳金 清博, Brain Tumor Pathology, 36, Suppl., 096, 096, 2019年05月
日本脳腫瘍病理学会, 日本語 - ヒステリーや発達障害と評価され診断が遅れた頭蓋内胚細胞腫瘍の2例
本田譲; 原和也; 寺下友佳代; 杉山未奈子; 長祐子; 井口晶裕; 山口健史; 中村明枝; 真部淳; 岡本迪成; 伊師雪友; 茂木洋晃; 山口秀; 森崇; 橋本孝之; 鬼丸力也; 平松泰好; 植竹公明; 佐藤正夫, 日本小児科学会雑誌, 123, 11, 2019年 - 脊髄神経膠腫におけるH3K27M変異と予後
伊師雪友; 関俊隆; 高宮宗一郎; 山崎和義; 濱内祝嗣; 山口秀; 寶金清博; 寶金清博; 石田雄介; 小田義崇; 飛騨一利, 日本脊髄外科学会プログラム・抄録集, 34th, 2019年 - 反復性髄膜炎を呈した前頭蓋底骨欠損に対して経鼻内視鏡手術を行った2例
伊師雪友; 茂木洋晃; 小林浩之; 小林浩之; 後藤秀輔; 館澤諒大; 岡本迪成; 山口秀, 日本神経内視鏡学会プログラム・抄録集, 26th, 2019年 - 脊髄神経膠腫の分子診断と予後
伊師雪友; 関俊隆; 高宮宗一郎; 山崎和義; 濱内祝嗣; 山口秀; 寳金清博; 飛騨一利; 石田雄介; 小田義崇; 田中仲哉; 茂木洋晃; 岡本迪成, 日本脳腫瘍学会プログラム・抄録集, 37th, 2019年 - 嗅神経芽細胞腫の進行度に応じた治療戦略決定のための新分類の提唱
茂木洋晃; 山口秀; 伊師雪友; 遠藤将吾; 小林浩之; 寺坂俊介; 鈴木正宣; 中丸裕爾; 本間明宏; 宝金清博, 日本脳腫瘍学会プログラム・抄録集, 37th, 2019年 - 膠芽腫に対するNovoTTF療法,当院における初期導入経験
山口秀; 茂木洋晃; 伊師雪友; 岡本迪成; 寺坂俊介, 日本脳腫瘍学会プログラム・抄録集, 37th, 2019年 - 下錐体静脈洞サンプリングにおけるアクセスルートMR venography
東海林菊太郎; 長内俊也; 藤間憲幸; 牛越聡; 茂木洋晃; 伊師雪友; 寳金清博, 脳血管内治療(Web), 4, Supplement, 2019年 - 鞍上部胚細胞腫のgrowing teratoma syndromeに対するpartial dubulkingの効果
岡本迪成; 山口秀; 伊師雪友; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 24th, 165, 2019年
日本語 - 膠芽腫において初期放射線治療終了後に残存病変がある場合の治療戦略についての検討
山口秀; 茂木洋晃; 伊師雪友; 岡本迪成; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 24th, 86, 2019年
日本語 - Meckel腔に進展した髄膜腫に対するRetrosigmoid Intradural Suprameatal Approach
茂木洋晃; 山口秀; 岡本迪成; 伊師雪友; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 24th, 131, 2019年
日本語 - FGFR1点変異を有する小児・若年成人低悪性度神経膠腫の臨床像
伊師雪友; 山口秀; 茂木洋晃; 小林浩之; 小林浩之; 寺坂俊介; 寺坂俊介; 寳金清博, Brain Tumor Pathology (Web), 36, Supplement, 093, 093, 2019年
日本脳腫瘍病理学会, 日本語 - 頭蓋内胚細胞腫瘍における放射線化学療法後のsalvage surgeryに関する病理所見からの検討
山口秀; 茂木洋晃; 伊師雪友; 岡本迪成; 井口晶裕; 長祐子; 杉山未奈子; 橋本孝之; 岡田宏美; 寳金清博, Brain Tumor Pathology (Web), 36, Supplement, 096, 096, 2019年
日本脳腫瘍病理学会, 日本語 - Lynch症候群への合併が疑われた膠芽腫の一例
伊師雪友; 伊師雪友; 小林智絵; 江藤和範; 能條建; 北川道生; 茂木洋晃; 山口秀; 小林浩之; 田中伸哉; 外丸詩野, Brain Tumor Pathology, 35, Supplement, 2018年 - Bevacizumab登場後の再発GBMに対する手術治療の役割の検証
山口秀; 小林浩之; 茂木洋晃; 岡本迪成; 伊師雪友; 越前谷すみれ; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 36th, 103, 2018年
日本語 - 神経線維腫症1型に合併したnon-optic gliomaの臨床像
伊師雪友; 山口秀; 茂木洋晃; 岡本迪成; 越前谷すみれ; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 36th, 83, 2018年
日本語 - Pilocytic astrocytomaやBRAF変異low-grade gliomaに対する手術の役割
山口秀; 小林浩之; 伊師雪友; 茂木洋晃; 岡本迪成; 越前谷すみれ; 寺坂俊介; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 23rd, 123, 2018年
日本語 - BRAF V600変異を有する成人高悪性度神経膠腫の臨床病理学的検討
伊師雪友; 山口秀; 吉田道春; 茂木洋晃; 小林浩之; 寺坂俊介; 寶金清博, 日本分子脳神経外科学会プログラム・抄録集, 18th, 2017年 - 簡便なリアルタイムマッピングによるMaximal safe removalを目指した錐体路近傍神経膠腫の手術
茂木洋晃; 山口秀; 寺坂俊介; 小林浩之; 遠藤将吾; 金子貞洋; 伊師雪友; 吉田道春; 宝金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 22nd, 2017年 - 急性の三叉神経障害と外転神経麻痺にて発症した三叉神経鞘腫の一例
高宮宗一朗; 茂木洋晃; 伊師雪友; 山口秀; 小林浩之; 寺坂俊介; 寶金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 22nd, 2017年 - ヒストンH3K27M変異を有する視床神経膠腫の3例
伊師雪友; 山口秀; 吉田道春; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 35th, 102, 2017年
日本語 - 成人の小脳高悪性度神経膠腫の分子生物学的特徴と臨床像
伊師雪友; 山口秀; 茂木洋晃; 吉田道春; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 22nd, 148, 2017年
日本語 - Bevacizumab登場後の再発悪性神経膠腫に対するmaximum resectionの有効性
山口秀; 寺坂俊介; 伊師雪友; 茂木洋晃; 小林浩之; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 22nd, 122, 2017年
日本語 - MRIとメチオニンPET所見から神経膠腫の病理診断や予後予測は可能か?
山口秀; 平田健司; 伊師雪友; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 35th, 158, 2017年
日本語 - 放射線照射中増悪を示す悪性星細胞腫に対するadd-on Bevacizumabの有用性
山口秀; 寺坂俊介; 茂木洋晃; 伊師雪友; 吉田道春; 小林浩之; 寶金清博, 日本脳腫瘍学会プログラム・抄録集, 34th, 2016年 - Grade2神経膠腫における形態学的Oligodendroglioma診断の意義
山口秀; 伊師雪友; 畑中佳奈子; 西原広史; 吉田道春; 遠藤将吾; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, Brain Tumor Pathology, 33, Supplement, 067, 067, 2016年
日本脳腫瘍病理学会, 日本語 - 様々な組織像を呈したBRAF変異を有する小児低悪性度神経膠腫の一例
伊師雪友; 山口秀; 畑中佳奈子; 藤田裕美; 吉田道春; 遠藤将吾; 小林浩之; 寺坂俊介; 寳金清博, Brain Tumor Pathology, 33, Supplement, 130, 130, 2016年
日本脳腫瘍病理学会, 日本語 - 神経膠腫摘出における錐体路リアルタイムマッピングの試み
茂木洋晃; 寺坂俊介; 小林浩之; 山口秀; 遠藤将吾; 金子貞洋; 伊師雪友; 吉田道春; 能條建; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 21st, 129, 2016年
日本語 - BRAFの変異に基づいた間脳毛様細胞性星細胞腫におけるMRI所見の特徴
伊師雪友; 山口秀; 畑中佳奈子; 藤田裕美; 吉田道春; 茂木洋晃; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 34th, 91, 2016年
日本語 - 初発の脳実質内病変における5-ALA蛍光診断と臨床像の相関性の検討
吉田道春; 山口秀; 伊師雪友; 遠藤将吾; 金子貞洋; 茂木洋晃; 小林浩之; 浅岡克行; 鴨嶋雄大; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 34th, 116, 2016年
日本語 - 総頚動脈直接穿刺にて急性期血行再建を施行した1 例
宮本倫行; 伊師雪友; 安喰稔; 安田宏; 牛越聡, Journal of Neuroendovascular Therapy, 9, 3, 2015年 - 悪性神経膠腫における初回残存病変の追加切除は予後延長に寄与するか?
山口秀; 寺坂俊介; 小林浩之; 茂木洋晃; 遠藤将吾; 伊師雪友; 吉田道春; 寶金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 20th, 2015年 - 錘体路近傍膠芽腫に対する錘体路リアルタイムマッピング
茂木洋晃; 寺坂俊介; 小林浩之; 山口秀; 金子貞洋; 遠藤将吾; 伊師雪友; 吉田道春; 能條建; 寶金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 20th, 2015年 - IDH/TERT遺伝子変異に基づいたGrade 3神経膠腫の予後再評価
山口秀; 伊師雪友; 吉田道春; 遠藤将吾; 小林浩之; 寺坂俊介; 寶金清博, 日本脳腫瘍学会プログラム・抄録集, 33rd, 2015年 - Grade3gliomaにおける5-ALA蛍光診断と臨床像の相関性の検討
吉田道春; 山口秀; 伊師雪友; 遠藤将吾; 茂木洋晃; 小林浩之; 浅岡克行; 鴨嶋雄大; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 20th, 128, 2015年
日本語 - 若年成人の神経膠腫に対するBRAFおよびH3F3A遺伝子変異検索の意義
伊師雪友; 山口秀; 吉田道春; 遠藤将吾; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍学会プログラム・抄録集, 33rd, 177, 2015年
日本語 - 特発性脊髄空洞症の臨床像
伊師雪友; 関俊隆; 飛騨一利; 笹森徹; 寳金清博, 日本脊髄外科学会プログラム・抄録集, 29th, 2014年 - 急性期脳梗塞治療における3T-ASLの有用性-意外に多い再開通後過灌流
宮本倫行; 伊師雪友; 安喰稔; 安田宏; 牛越聡, Journal of Neuroendovascular Therapy, 8, 6, 2014年 - 硬膜動静脈瘻における3T-ASLの有用性の評価-特にshort time post labeling delayの併用について
宮本倫行; 伊師雪友; 安喰稔; 安田宏; 牛越聡, Journal of Neuroendovascular Therapy, 8, 6, 2014年 - 全身血管病に起因する頸部内頸動脈解離性動脈瘤対してStent assisted coil embolizationが有効であった一例
高宮宗一朗; 長内俊也; 牛越聡; 栗栖宏多; 下田祐介; 伊藤康裕; 伊師雪友; 中山若樹; 数又研; 鐙谷武雄; 七戸秀夫; 寶金清博, Journal of Neuroendovascular Therapy, 8, 6, 434, 2014年
日本語 - 化膿性脊椎炎に対して後方固定術を施行した1例
伊師雪友; 伊師雪友; 青山剛; 矢野俊介; 飛騨一利; 笹森徹; 山内朋裕; 村田純一, Neurological Surgery, 41, 11, 2013年 - 松果体部に生じた原発性横紋筋肉腫の一例
伊師雪友; 寺坂俊介; 山崎和義; 茂木洋晃; 小林浩之; 寳金清博; 井口晶裕; 長祐子; 大島淳二郎; 佐藤智信, 日本脳腫瘍の外科学会プログラム・抄録集, 18th, 2013年 - 難治性慢性硬膜下血腫で再発した嗅神経芽細胞腫の一例
伊師雪友; 寺坂俊介; 茂木洋晃; 栗栖宏多; 小林浩之; 寳金清博; 山田洋介; 畑中佳奈子, 北海道医学雑誌, 88, 2/3, 2013年 - 「特発性」が示唆されたfourth ventricle outlet obstructionの治療例
伊師雪友; 伊師雪友; 小林浩之; 茂木洋晃; 浅岡克行; 杉山拓; 杉山拓; 越前谷すみれ; 横山由佳; 板本孝冶, 小児の脳神経, 38, 1, 122, 122, 2013年, [査読有り]
(一社)日本小児神経外科学会, 日本語 - 補助人工心臓装着患者の脳塞栓症に対して急性期血管内治療が奏功した1例
小林聡; 宮本倫行; 品田伸一郎; 伊師雪友; 下田祐介; 山崎和義; 牛越聡; 宝金清博, Journal of Neuroendovascular Therapy, 7, 6, 316, 2013年
日本語 - 化膿性脊椎炎の一手術例:治療方針の検討
伊師雪友; 伊師雪友; 青山剛; 矢野俊介; 飛騨一利; 笹森徹; 山内朋裕; 村田純一; 斎藤久寿, 日本脊髄外科学会プログラム・抄録集, 27th, 2012年 - 巨大延髄背側血管芽腫の治療経験
伊師雪友; 山崎和義; 栗栖宏多; 濱内祝嗣; 下田祐介; 浅野剛; 長内俊也; 小林浩之; 寺坂俊介; 寳金清博, 日本脳腫瘍の外科学会プログラム・抄録集, 17th, 2012年 - 中年女性に発症したCNS PNET with epithelial differentiationの一例
伊師雪友; 津田宏重; 高杉和雄; 鈴木望; 立野正敏; 田中伸哉, 日本脳腫瘍学会プログラム・抄録集, 27th, 2009年 - 脳腫瘍に対するステロイド治療により,カリニ肺炎を合併した3例
津田宏重; 伊師雪友; 高杉和雄; 鈴木望, 日本脳腫瘍学会プログラム・抄録集, 27th, 2009年
- 全科臨床実習, 2024年, 学士課程, 医学部
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 神経障害学Ⅱ, 2024年, 学士課程, 医学部
- 脳神経外科学, 2024年, 学士課程, 医学部
- 悪性末梢神経鞘腫に対するEZH2阻害薬を用いたセルメチニブ感受性増強効果の検証
科学研究費助成事業
2025年04月01日 - 2028年03月31日
伊師 雪友
日本学術振興会, 若手研究, 北海道大学, 25K18921 - AT/RTに対するEZH2阻害薬を用いた免疫チェックポイント阻害薬の作用増強効果の検証
科学研究費助成事業
2024年04月01日 - 2027年03月31日
金子 貞洋; 伊師 雪友; 茂木 洋晃; 山口 秀
日本学術振興会, 基盤研究(C), 北海道大学, 24K10397 - 疾患特異的iPS細胞を用いた神経線維腫症2型の病態解析と新規治療法の探索
科学研究費助成事業
2019年04月01日 - 2022年03月31日
寺坂 俊介; 江良 択実; 伊師 雪友; 小林 浩之; 山口 秀
神経線維腫症2型(NF2)の患者5名から採取した末梢血単核球を用いて、iPS細胞の誘導を行った。樹立したすべての患者由来iPSC(NF2-iPSC)において、幹細胞マーカーの発現を認めた。体細胞モザイクの症例から樹立したNF2-iPSCではクローン毎にNF2遺伝子異常の有無が異なったが、NF2に関連するシグナル経路の遺伝子発現はこれらのクローン間で差を認めず、NF2遺伝子の両アレルの不活性化が腫瘍化に必要であることが示唆された。シュワン細胞への分化誘導による腫瘍モデルの樹立を試みたが、健常人由来iPSCを用いてneural crestからシュワン細胞へ分化させる条件が整わず断念した。
日本学術振興会, 基盤研究(C), 北海道大学, 19K09519 - 低悪性度神経膠腫に対する蛍光診断:ポルフィリン代謝分子に対する機能解析
科学研究費助成事業
2019年04月01日 - 2022年03月31日
山口 秀; 伊師 雪友; 小林 浩之
Grade 2,3の低悪性度神経膠腫摘出術では、5-ALAの蛍光ガイド下摘出術で必ずしも陽性が得られない。我々は、ポルフィリン合成経路に着目し、遺伝子発現解析を行って、低悪性度神経膠腫における腫瘍蛍光に関与する分子の同定を行った。この結果、Peptide transporter 2 (PEPT2)の発現亢進が蛍光発光陽性の腫瘍において認められることが判明した。神経膠腫細胞株を用いPEPT2の発現をsiRNAを用いて低下させたところ、蛍光発光が減弱することが確認された。以上より、PEPT2の発現亢進が低悪性度神経膠腫における蛍光発光に関与している可能性が示唆された。
日本学術振興会, 基盤研究(C), 北海道大学, 19K09495 - 疾患特異的iPS細胞を用いたATRX変異神経膠腫におけるテロメア伸長機構の解明
科学研究費助成事業
2019年04月01日 - 2021年03月31日
伊師 雪友
まず健常人由来のiPS細胞からアストロサイトを誘導する予備実験として、201B7細胞を用いてfeeder freeの状態でNeural Induction Mediumでの培養を行った。得られた細胞は蛍光免疫染色でNestinおよびPAX6で陽性であり、神経幹細胞としての性質を有していると考えられた。次に神経幹細胞からアストロサイトを誘導するために、DMEM培地を基本として各種の分化誘導因子を加えて培養を行ったが、いずれも十分なGFAP陽性の細胞が得られなかった。今後は神経幹細胞からアストロサイトを誘導する条件をさらに検討し、ATRX症候群の患者由来iPS細胞でも同様の実験を行う予定である。
日本学術振興会, 若手研究, 北海道大学, 19K18412
